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The prostate is a gland that lies underneath the bladder and surrounds the 
urethra, the tube through which urine passes from the bladder to the penis 
(Figure 1). It is only found in men and about the size and shape of a walnut. 
The prostate gland’s main function is to produce prostate fluid, a constituent of 
semen that protects the sperm cells (1).
Figure 1. Graphical representation of the prostate gland. This figure is adapted 
from Turbosquid, (2014), male genitals [ONLINE]. 
Available at: http://www.turbosquid.com/3d-models/male-reproductive-
penis-prostate-3d-model/233868 [Accessed 12 October 14].
Three main conditions can affect the prostate and can be generally associated 
with aging in men. The most common is called benign prostate hyperplasia 
(BPH), characterised by non-cancerous prostate tissue overgrowth that can 
cause pain and trouble with urination. The second condition is called prostatitis; 
it is caused by either an infection or an inflammation and it can often be treated 
with antibiotics or other drugs such as non-steroidal anti-inflammatory drugs 
(NSAIDs) (2). The third condition is prostate cancer (PCa), the second most 
common type of cancer seen in men nowadays, and the sixth leading cause of 
cancer death among men worldwide (3, 4). 
Some prostate cancers grow very slow and do not cause symptoms unless the 
subject lives a long life. Other prostate cancers grow quickly and they can result 
in death if not detected and treated on time. The probabilities of survival are 
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Prostate Cancer diagnosis
higher when PCa is diagnosed early. In general, 85% of men survive PCa after five 
years, but this numbers are affected by the stage, i.e. men with metastatic disease 
(Stage IV) at diagnosis, could have a 5-year survival rate of around 30% (5, 6). 
When the cancer is localized (or confined) to the prostate, it can be monitored 
by active surveillance and/or watchful waiting to avoid unnecessary treatment 
and possible side effects. PCa can be effectively treated by radical prostatectomy 
(RP), which is a surgery that removes the entire prostate gland, and also by 
radiation treatment such as Brachytherapy or External Beam Radiation Therapy 
(EBRT) in which X-ray beams are directed towards the prostate, thus damaging 
cancer cells and stopping their growth. Radiotherapy is used when the cancer 
has spread outside the prostate or when the prostate specific antigen (PSA) 
rises after removing the prostate (also known as biochemical recurrence BCR). 
However, the choice of radiotherapy depends also on both patient’s health and 
preference, as this treatment could be drastic when life expectancy is low.
In case of metastatic disease, or when primary treatment is not used, hormone 
treatments based on the suppression of testicular androgens by either chemical 
or surgical castration, are the mainstay treatment. They are aimed to reduce the 
levels of male hormones (androgens: DHT and testosterone) in the body, thus 
stopping the ‘fuel’ needed for the cancer cells to grow. Antiandrogen drugs such 
as flutamide, bicalutamide and nilutamide, block testosterone and DHT binding 
to the AR and thereby the ability of prostat tissue to use andrigens. However, 
these treatments do not cure cancer and in most cases become ineffective after a 
certain period of time (7, 8). Metastatic prostate cancer usually responds well to 
hormone therapy, but, in some cases, cancer cells adapt themselves to grow in an 
hormone-reduced environment, thus becoming hormone-resistant PCa.
Chemotherapy involves the use of anti-cancer drugs such as docetaxel or 
carbazitaxel to kill cancer cells. Although this treatment does not cure PCa, in 
many patients it slows its growth.
Some risk factors make men more likely to suffer from PCa. The biggest risk 
factor associated with PCa is generally age, but family history and ethnicity 
have been also considered as risk factors to develop PCa (9). Lifestyle also might 
play a role in the development of PCa, associations between PCa and physically 
inactive lifestyles, consumption of saturated and unsaturated fats, excessive 
smoking and alcohol drinking, might be present (10-12).
The most commonly used diagnosis of PCa are the digital rectal examination 
(DRE) and the prostate-specific antigen (PSA) test. DRE is used to feel whether 
any bump or hard/irregular area is present on the prostate. PSA tests measure 
the amount of the kallikrein-related peptidase (KLK3) in blood. This protein 
is produced by cells in the prostate and secreted to the seminal fluid in large 
quantities. An alteration of cellular barriers that normally keep PSA within the 
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ductal system of the prostate usually occurs during the development of PCa, 
thus altering blood levels of PSA. 
Although the introduction of PSA screening decreased mortality by 4% between 
1994 and 2006 (13), the use of PSA as a diagnostic serum marker still presents 
several drawbacks. The concentration of this protein in the blood increases 
during the development of cancer but also due to the other above-mentioned 
prostate alterations: BPH or prostatitis. Therefore, this method suffers from 
low specificity and, consequently, results in incorrect risk assessment and 
unnecessary biopsies. It is known that the proportion of men with a positive test 
result who actually have PCa, using a PSA cut-off value of ≥ 3 ng/mL, is 24% 
according to European Randomised study for Prostate Cancer (ERSPC) (14). 
When using a  cut-off value of 1.0 ng/mL, the proportion decreases to 10% (15). 
Moreover, approximately 15% of patients with PCa have PSA values lower than 
the cut-off value of 4.0 ng/mL, thus leaving many cases undetected. The actual 
PCa diagnosis is performed by means of an ultrasound guided biopsy of the 
prostate, and its subsequent histological analysis.
A prostate biopsy involves the removal of tissue core samples mainly from the 
peripheral zone (the outer part) of the prostate gland. Usually, 6 to 14 cores are 
taken and analysed by a pathologist and, subsequently, the stage and grade of 
the disease are determined. Grading of PCa, an estimation of the ductal structure 
differentiation of the disease, is performed according to the Gleason system. This 
system is based on the assignment of a grade using numbers (from 1 to 5) to the 
cells in cancerous tissue depending on how similar they are to normal prostate 
tissue. Since PCa usually exhibits areas with different grades, the grading is 
performed on two areas that make up most of the cancer. These two grades are 
reported together as the Gleason Score, with values ranging from 2-10. Scores 
are considered non aggressive when the values are within 2-4; mildly aggressive 
for values between 5-6;  moderately aggressive when the score is 7; and very 
aggressive for scores between 8-10 (16). More recently, the International Society 
of Urological Pathology (IUSP) proposed a modified classification using a scale 
from 1-5 where Gleason 6 is considered group 1. Gleason 3+4=7 and 4+3=7 are 
now considered as prognostic groups 2 and 3, respectively, Gleason 8 is the 
prognostic group 4 and Gleason 9-10 fall into group 5 (17, 18).
Stage of PCa is an estimation of how extensive or advanced is the PCa and 
whether it has metastasized, or spread, beyond the prostate gland. The TNM 
system (Tumour Node Metastasis) is the most common method to stage PCa, 
involving different clinical tests such as CT scans, MRI or bone scans. TNM 
provides information about the tumour itself (T), the regional nodes (N) in case 
the cancer has spread to the lymph nodes or bone, and also about the distant 
metastasis (M) occurring beyond the pelvis. Clinical outcomes from patients with 
stages I/II of prostate cancer are good, with up to 99% progression-free survival 
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Biochemical recurrence
Markers for prostate cancer
after 1 year and over 90% after five years. However, for patients diagnosed at 
stage III and stage IV, survival decreases to 85% in the first years and 30-40% 
after 5 years (6, 17, 19).
Taken together, PSA values, Gleason Scores and TNM stages allow the 
determination of the PCa risk factor for a patient, and constitute a help for 
clinicians to determine what kind of treatment is more appropriate for a specific 
condition.
Among men diagnosed as having PCa, assessment of disease recurrence 
after primary treatment typically includes periodic measurements of PSA. 
A detectable PSA level after radical prostatectomy, or an increasing PSA level 
following radiation therapy, is considered as biochemical recurrence (BCR) or 
“PSA failure” (20). BCR is associated with increased PCa mortality and it can 
indicate disease progression years before clinical signs or symptoms appear. 
After radical prostatectomy, PSA usually becomes undetectable within 6 weeks 
after surgery because the most important source of PSA (the prostate gland) 
was removed. However, detectable PSA levels after surgery are observed in 
approximately 35% of men (21) and it most likely implies residual or recurrent 
PCa. In general, a cut-off point of 0.2 ng/mL or higher after undetectable PSA is 
accepted to define BCR after radical prostatectomy (21, 22).
A marker can be defined as a characteristic objectively measured molecule or 
feature that can be evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention 
(23). In a broad perspective, “an ideal marker for general use in PCa 
management should be able to differentiate tumour tissue from benign tissue, 
and an aggressive tumour from an insignificant one, with high specificity and 
sensitivity” (24). In addition, it should be available at preferably low-cost, and 
as a non-invasive test to encourage widespread use (25). Markers for PCa can 
be classified into five categories: risk, diagnostic, prognostic, predictive and 
monitoring (Table 1), thus allowing an improvement in the management of PCa 
(26). Technological progress, particularly in the so-called “omics” era of next-
generation sequencing and mass spectrometry, continuously provides new 
options for higher throughput and higher content DNA, RNA, protein and 
metabolite detection (25, 27-30)
In the following lines, some examples of known markers in serum/plasma, 
urine and tissue are described.
PSA is one of the fifteen family members of kallikrein-related peptidases, and 
the analysis of its level in serum revolutionized the management of PCa. PSA 
shares biochemical similarities with the other gene family members and their 
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use in the management of PCa has involved the analysis of various molecular 
forms of PSA (free, intact, complexed PSA, and pro-PSA) (31, 32). 
The prostate health index (PHI), aims to diagnose healthy and malignant prostate 
conditions in men older than 50, and with normal DRE and PSA values lower 
than 4 ng/mL. This test included the analysis three PSA isoforms followed by 
the formula [-2] proPSA / fPSA x PSA1/2. Another test, the 4K score, combines 
the analysis of the three isoforms included in the PHI, together with the 
kallikrein-related peptide (hK2) assessment, and clinical information such as age 
and history before biopsy. Although these tests have gained attention in the last 
years for the detection of PCa, prospectives studies are still needed to evaluate 
their use as screening tool for the early diagnosis of PCa (33).
In urine, the PCA3 assay involves the analysis of prostate cancer antigen 3 
(PCA3), a non-coding gene which is highly expressed in PCa cells and produced 
only in prostate tissue. The PCA3 assay measures the mRNA in urine after DRE 
and it is more specific than PSA, which is secreted by all prostate cells and can 
be influenced by prostate volume (25, 34). Initial findings suggest that the PCA3 
assay does identify cancer, but does not discriminate between low risk and 
aggressive disease (35, 36).
A urinary marker that detects TMPRSS2 fused with ERG has been reported 
to yield more than 90% specificity and 94% positive predictive value for PCa 
diagnosis (37), however, the sensitivity is low since only 40-50% tumours carry 
this fusion. Prognostic performance also based on tissue expression remains 
controversial (37). In addition, it has been shown that urine TMPRSS2:ERG, in 
combination with urine PCA3, enhances the utility of serum PSA for predicting 
prostate cancer risk and clinically relevant cancer on biopsy (37, 38). 
In tissue, different multi-gene expression assays have been developed from 
prostate needle biopsies. The Oncotype DX test measures the expression of 12 
cancer-related genes discriminating four biological functions such as androgen 
signalling, proliferation, cytoskeletal organization and stromal response (39). 
The Prolaris test, uses expression analysis of 46 genes together with Gleason 
score and PSA to predict cancer aggressiveness (40).
At protein level, the immunohistological detection of the AMACR protein, 
which is overexpressed in most prostate cancers (41), has been proposed as a 
test for detecting PCa. AMACR has been proposed as a novel drug target for 
PCa and it has been demonstrated that diminution of AMACR protein levels 
using siRNA methods reduced proliferation of the androgen-dependent LAPC-
4 PCa cell line. (41-44). A prognostic assay, ProMark, has been also proposed to 
predict PCa aggressiveness, by means of the quantitative analysis of 8 proteins 
(DERL1, CUL2, SMAD4, PDSS2, HSPA9, FUS, phosphorylated S6, and YBOX1) 
using immunofluoresence on biopsy tissue sections.
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Type of 
marker
Most common current 
markers
Less commonly
used and emerging 
molecular markers
Risk Family history, urinary 
symptoms, age, race 
Single nucleotide 
polymorphisms (SNPs), 
rare variants of HOXB13 
and germline BRCA 
mutations, PSA at age 40-
50.
Diagnostic PSA and PSA-based markers 
(Age-adjusted PSA, PSA 
doubling time, PSA velocity, 
free PSA, Percent-free PSA, 
ProPSA, PSA density), DRE, 
biopsy histopathology 
AMACR/p63 or ERG IHC, 
imaging (MRI, CT, TRUS) 
Prostate Health Index 
(PHI), PCA3, TMPRSS2- 
ERG, marker profiles of 
differentially expressed 
and mutated genes in 
urine and blood 
Prognostic Gleason score (biopsy), 
extend of disease in biopsies, 
imaging (CT, MRI bone scan), 
after prostatectomy pT stage, 
Gleason grade and surgical 
margins 
PTEN, c-MYC and 
expression of other 
oncogenes and tumour 
suppressor genes in 
tissue (biopsies), miRNA 
profiles in serum, urine 
and tissue, imaging.
Predictive Androgen receptor 
variants (indicating 
resistance to hormonal 
therapy), mutations in 
DNA repair genes.
Monitoring PSA, imaging (MRI, CT, bone 
scan) 
EpCAM capture and 
molecular characteristics 
of CTCs, imaging. 
Altered metabolism in PCa
Table 1. Current and emerging markers for PCa management. Adapted from 
the article: Are there usable molecular markers for prostate cancer? Jenster, G., 
European Urology Today: EUT Congress News. March 2015.
Cancer is a complex genetic disease that results into deregulation of 
various metabolic mechanisms including bioenergetics. With technological 
improvements, the focus of cancer research has gradually shifted from changes 
in an individual biochemical pathway or metabolite, towards changes in the 
context of the global network of metabolic pathways, in a cell tissue or organism 
(45). 
In multicellular organisms, most normal cells are exposed to a constant supply 
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of nutrients. In order to prevent an aberrant and uncontrolled cell proliferation, 
organisms use control growth factors that prevent and regulate the uptake 
of nutrients when their availability exceeds the levels needed to support cell 
division. In cancer cells, this growth factor dependence is overcome by acquiring 
genetic mutations that functionally alter receptor-initiated signalling pathways. 
These oncogenic mutations can result in the uptake of nutrients, particularly 
glucose, that meet or exceed the bioenergetics demands of cell growth and 
proliferation (also known as ‘Metabolic reprograming’, nowadays recognised 
as one of the hallmarks of cancer (46-48). It has been observed already by 
Warburg (1924, Nobel Prize) that cancer cells have different metabolic features, 
fermenting glucose into lactate even in the presence of enough oxygen to support 
mitochondrial oxidative phosphorylation (47, 49, 50).
One of the major functions of prostate cells is the production of citrate, PSA, and 
polyamines, such as spermine and spermidine, which are the major components 
of prostatic fluid. Prostate cells have a distinct metabolic profile as they produce 
specific compounds. Metabolic reprogramming in PCa is different compared to 
the reprogramming observed in other cancers. In normal prostate cells, there 
is an accumulation of zinc that produces the enzymatic activity inhibition of 
mitochondrial aconitase (the enzyme that catalyses the conversion of citrate to 
D-isocitrate) and therefore a truncated TCA cycle. In prostate cancer cells, zinc 
transporters are down-regulated, resulting in the enzymatic inhibition relieve 
of aconitase, thus enabling the utilisation of citrate through the mitochondrial 
TCA cycle, the decreased accumulation of polyamines, and the increased ATP 
production that provide energy for accelerated proliferation (51, 52).
Oxaloacetate and acetyl-coenzyme A (acetyl-coA) are essential for citrate 
synthesis, but whereas oxaloacetate is regenerated in the Krebs cycle, acetyl-
coA is consumed. It is necessary to maintain elevated rates of citrate oxidation, 
with the subsequent availability of acetyl-coA, to ensure that cancer cells have 
the needed energy for rapid proliferation. It has been proposed that to maintain 
this accelerated citrate oxidation, alterations in the fatty acid metabolism (both 
saturated and unsaturated) are needed to provide both ATP and acetyl-coA (51, 
52). A schematic representation of the major metabolic pathways altered in PCa 
is shown in Figure 2.
Beyond Krebs cycle and glycolysis, glucose can be degraded through the pentose 
phosphate pathway. This metabolic pathway involves the production of NADPH 
and ribose-5-phosphate, which are associated to nucleotide and nucleoside 
biosynthesis (51). It has been reported that Androgen Receptor signalling 
increases the levels of glucose-6-phosphate dehydrogenase (G6PD), NADPH, as 
well as ribose synthesis in hormone-sensitive PCa cells, thus confirming the role 
of the pentose phosphate pathway in PCa growth (51, 53).
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Cell proliferation and intercellular signalling are dependent on increased 
lipid biosynthesis. Acetyl-coA also plays an important role in this metabolic 
alteration because it is a precursor for lipogenesis and cholesterolgenesis 
and can be produced by transformation of citrate in the cytosol (51).  Sterol 
regulatory element binding protein 1 (SREBP1) an essential transcription factor 
for lipogenesis, is also implicated in AR transcriptional regulation. It is known 
that beyond lipogenesis, SREBP1 also increases reactive oxygen species (ROS) 
production and the expression of NADPH oxidase, which leads to proliferation, 
migration, and invasion of PCa cells (54).
In PCa cells, the levels of choline and creatine are increased because of a higher 
rate of membrane synthesis during cell proliferation (52). Glutamine also has 
an important role in the maintenance of lipogenesis, as well as to provide 
intermediates for the Krebs cycle through glutaminolysis. Glutamine transporter 
and glutaminase have been shown to be overexpressed in PCa, the role of these 
enzymes in PCa development and progression is still unknown (52). 
Figure 2. Altered metabolic pathways in PCa (Figure adapted from references 
42-44). A major and persistent characteristic that distinguishes normal prostate 
tissue from malignant PCa tissue is the high level of citrate content, caused by 
the accumulation of Zn.
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Metabolomics approaches in PCa research
Metabolites are intermediate and end products of the cellular regulated 
processes and their levels can be regarded as the biochemical signature of the 
overall phenotype of a system at a certain stage or phase of development, taking 
into account both genetic as well environmental influences (45). 
Metabolomics aims to comprehensively identify small molecules (metabolites) 
to gain insight into cellular signalling pathways underlying disease and to 
discover novel biomarkers for screening, early diagnosis, prognosis and 
response to specific treatment. Metabolomics is interdisciplinary, driven by 
basic sciences (analytic biochemistry, biology) and bioinformatics, together with 
epidemiology and clinical research (55). Metabolomics is an important tool in the 
study of human diseases because metabolites constitutes the readout of gene-
environment interactions and may therefore be complementary biomarkers 
than single nucleotide polymorphisms (SNPs) or epigenetic markers (56). Mass 
spectrometry (MS)-based techniques have the specific advantages of being more 
sensitive and therefore superior in terms of metabolic coverage, compared to 
nuclear magnetic resonance (NMR). Metabolomic experiments can be divided 
into targeted and untargeted analysis: the former aims to accurately determine 
concentrations of determined subset of metabolites, obtained from a defined 
pathway, whereas the untargeted approach uses a more global approach to 
cover the maximum number of metabolites that can be detected by an analytical 
method (45, 55).
Different studies describing metabolic alterations associated to PCa have been 
reported in literature in the last decade. These studies included metabolomics 
experiments in body fluids such as urine, plasma or serum from PCa patients, as 
well as metabolomic profiling in PCa tissue and cell lines. Major findings in the 
application of metabolomics approaches in PCa are 
summarised in Table 2.
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Table 2. Applicability of metabolomics in the diagnosis and prognosis of PCa.
Sample Analytical 
methodology
Findings: Metabolites or class of
 metabolites
Cancer Type or 
condition
Ref.
Up-
regulated
Down-
Regulated
Urine, 
Tissue
GC-LC/MS Sarcosine, proline, kynurenine, uracil and glycero-3-phosphate
PCa vs
 Normal (57)
Sarcosine
PCa 
progression to 
metastasis
(57)
Urine
GC-LC/MS Sarcosine is not elevated in PCa PCa vs Normal
(58-60) 
Reviewed 
by Trock et 
al, kers in 
Ref (61)
HPLC-MS/MS
Kynurenine, Proline, 
glycerol-3-phosphate and uracil are not 
reliable markers for detecting or differentiat-
ing the aggressiveness of PCa
PCa vs 
Normal (62)
GC-LC/MS Urea cycle, TCA cycle, amino acids, purines
PCa vs 
Normal (63)
GC/MS Fatty acids Pyrimidines, creatinine, purines, glucosides
PCa vs 
Normal (64)
1H NMR Sarcosine, ala-nine, pyruvate Glycine
High-grade and 
Low-grade PCa 
vs Normal
(65)
LC-HRMAS Tryptophan metabolites
Thymine metabolites, 
nitrogen metabolites, 
tri-peptides
PCa vs 
Normal (66)
Serum UHLPC-MS
Hexadecaenoic 
acid, trypto-
phan, steroid 
hormone
metabolites
Phenylalanine, 
lysophospholipids
PCa vs
 Normal (26)
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Serum
HPLC-FLD Non-altered tryptophan and kynurenine PCa Gleason 
6&7 vs
Normal
(67)
UHPLC-MS/
MS
HETEs Arachidonic acid PCa vs Normal 
and different 
stages of PCa
(68)
LC/MS Deoxycholic acid, glycochenodeoxycholate, 
tryptophan, docosapentaenoic acid, arachi-
donic acid, deoxycytidine triphosphate and 
pyridinoline
PCa patients be-
fore and during 
endocrine 
therapy
(69)
LC/MS 38:5 egg phosphatidylcholine (ePC), 40:3 
(PC) and 42:4 (PC)
PCa vs Normal (70)
Tissue
HRMAS 1H 
NMR Spermine, citrate
PCa vs Normal, 
Low -grade PCA 
vs High-grade 
PCa
(71)
GC-LC/MS
Aminoadipic 
acid, cerebronic 
acid, glycer-
ophosphoe-
thanolamine, 
2-hydroxy-
behenic acid, 
isopentenyl 
pyrophosphate, 
7-methylgua-
nine and tricosa-
noic acid
Gluconic Acid, 
Maltotriose
PCa vs 
Normal (72)
1H HR-MAS
Lysine degrada-
tion, fatty acids, 
sugars
Mevalonate metabolism, 
purines
PCa vs 
Normal (73)
UHPLC-MS/
MS
Amino acids, 
carnitines, 
purines, pyrimi-
dines, choline, 
Laureate, malate, 
mannose, ADP
E x t r a c a p s u l a r 
extension PCA 
vs organ-con-
fined PCa
(74)
NAD+, choline 
derivatives, 
Polyamine, fatty acids, 
sugars
Extracapsular 
extension PCa vs 
seminal vesicle 
PCa
(74)
Prostate 
cancer 
cells
LC/MS
Sarcosine, 
threonine, 
phenylalanine, 
alanine, nitrogen 
metabolites
Tryptophan PCa vs Normal (75)
LC/MS Homocysteine, polyamines S-Adenosylmethionine
AR dependent vs 
Androgen
 Independent
(76)
LC/MS
Amino sugars, 
methylation me-
tabolites, Amino 
acids
Sugars, energy signaling AR-dependent PCa vs CRPC (75)
LC/MS
17-HpDHA and 17-HDHA are potent inhib-
itors of proliferation on androgen positive 
and negative PCa cell lines
Proliferation
 inhibition (77)
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Polyunsaturated fatty acids (PUFA) play a key role in the structure and 
physiological properties of cell membranes. Two classes of PUFA, designated 
as w-6 and w-3 (indicating the position of the C=C double bond), normally are 
present in tissue and body fluids. These fatty acids cannot be synthesized by 
mammalian cells, and need to be obtained from the diet. It is known that the 
Western diet usually contains 10- to 20-times more w-6 than w-3 PUFA.  Plasma 
and most other tissues are richer in w-6 fatty acids, but the brain and retina are 
considered exceptions because they are rich in w-3 PUFA. Absence of w-6 PUFA 
could cause a very serious systemic illness called essential fatty acid deficiency 
(78). 
The need for arachidonic acid (20:4n-6), almost certainly is the primary reason 
why w-6 PUFA are essential. Arachidonic acid is the main substrate for synthesis 
of the eicosanoid mediators it is highly enriched in the inositol phospholipids 
that are involved in signal transduction (79).
Arachidonic acid (AA, or sometimes ARA) is a polyunsaturated omega-6 fatty 
acid 20:4(w-6) (Figure 3). It is the counterpart to the saturated arachidonic 
acid found in peanut oil. AA is present in phospholipids -especially 
phosphatidylethanolamine, phosphatidylcholine, and phosphatidylinositides- 
of membranes of the cells, and is abundant in brain, muscles and liver. The 
four cis double bonds in the arachidonic acid molecule confer it high mobility 
and flexibility, thus helping it to provide mammalian cell membranes their 
correct fluidity at physiological temperatures. In addition, the double bonds are 
responsible for the tendency of arachidonic acid to react with molecular oxygen 
(78, 79). 
Dietary fat intake might be one of the most studied dietary risk factors for 
PCa, although its role in influencing cancer risk remains controversial (80). It 
has been observed in PCa cell lines that n-6 fatty acids, such as linoleic acid 
and arachidonic acid (AA), promote cell proliferation, whereas long-chain 
polyunsaturated n-3 fatty acids, might inhibit cell proliferation (81). Thus, these 
promotional and inhibitory effects of n-6 and n-3 fatty acids, respectively, have 
motivated the study of dietary fatty acids in the development and progression 
of PCa. 
Arachidonic acid pathway
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Figure. 3. Chemical structure of arachidonic acid.
AA is released from a phospholipid molecule in cell membranes by the 
enzyme phospholipase A2 (PLA2), which cleaves off the fatty acid. AA can 
also be generated from diacylglycerol (DAG) by a DAG-lipase enzyme. AA 
generated for signalling purposes appears to be derived by the actions of a 
phosphatidylcholine- specific cytosolic phospholipase A2 (cPLA2), whereas 
inflammatory AA is generated by the action of a low molecular weight secretory 
PLA2 (sPLA2) (82). 
AA is a precursor in the production of eicosanoids: signalling molecules 
produced by oxidation of twenty-carbon fatty acids. Three families of enzymes 
catalyse the oxidation of fatty acids to produce eicosanoids: Cycloxygenases, 
lipoxygenases and epoxygenases. Cycloxygenases (COX-1 and COX-2) lead to 
prostaglandin H2 (PGH2), which in turn is used to produce the prostaglandins (PGs), prostacyclins (PGIs) and thromboxanes (TXs). Lipoxygenases (5-LOX, 12-
LOX, 15-LOX and 15-LOX-2) produce hydroxyeicosatetraenoic acids (HETEs) 
and leukotrienes (LTs). Epoxygenases (including the family of Cytochrome P450 
enzymes) produce also HETEs and epoxyeicosatrienoic acids (EETs) (81, 83). 
The production of these derivatives and their action in the body are collectively 
known as the AA pathway.
The PGs are synthesized by the action of COX enzymes: the constitutively 
expressed COX-1 and the inducible COX-2. COX-2 can be stimulated by 
inflammatory mediators, cytokines, growth factors, and tumour promoters and 
can be inhibited by steroids and certain nonsteroidal anti-inflammatory drugs. 
Both AA and PGE2 stimulate cell proliferation and tumour growth in vitro in PC-3 human PCa cells (84). In PC-3, LNCaP, and DU145 prostate cancer cell 
lines, upregulation of COX-2 and PGE2 was reported to be inversely correlated 
with apoptosis (85).
LOX products, such as LTs and hydroxyeicosatetraenoic acids (HETEs), as well 
as TXs, metabolites of COX enzymes, have been studied during proliferation of 
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various human cancer cell lines. Expression of 12-LOX was reported to stimulate 
angiogenesis in human PCa cells (81). The 5-LOX product 5-HETE has been 
suggested to play role as a potent pro-growth survival factor for human prostate 
cancer cells (86). 
Aim and outline of the thesis
Although the introduction of prostate-specific antigen (PSA) has improved 
considerably the management of PCa, its lack of specificity in the diagnosis 
and prognosis has motivated the search for novel and non-invasive molecular 
markers as well as novel therapeutic targets for treating prostate carcinoma. 
In this thesis, we aimed to identify and validate novel metabolites or proteins in 
tissue or bio-fluids, which might improve the diagnosis and/or the prognosis 
of PCa. To accomplish this aim, we used both metabolomics and proteomics 
methodologies, and particularly we used the state of art of mass spectrometry 
(MS) for the identification and quantitation of both metabolites and proteins in 
serum and PCa tissue. 
Kynurenine, a metabolite produced along the tryptophan pathway, was reported 
a few years ago as a metabolite-deregulated in PCa.  In Chapter 2, we aimed 
to validate the role of kynurenine as a diagnostic marker for PCa by analysing 
concentrations of kynurenine (Kyn) and tryptophan (Trp), in serum samples 
from PCa patients exhibiting different Gleason Scores as well as controls. We 
demonstrate that neither the concentrations of these metabolites, nor the ratio 
Kyn/Trp, an indicator of the Indoleamine 2-3 dioxygenase (IDO) activity, cannot 
be considered as new markers for detecting PCa.
Arachidonic acid (AA) has been proposed to play a role in PCa development 
and progression. Particularly, lipoxygenases, a type of enzymes responsible of 
incorporating a hydroxyl group to the arachidonic chain, have been shown to be 
altered in PCa biopsies and cancer cell lines. In addition, concentrations of AA 
have been reported to be diminished in PCa tissue. In Chapter 3, we aimed to 
study concentrations of arachidonic acid, five of its metabolites (HETEs) in serum 
from PCa patients, and aimed to analyse their potential in the diagnosis and 
prognosis of the disease. We found that concentrations of HETE metabolites were 
higher in a selected group of patients at the most advanced stages of the disease. 
Although our markers do not exhibit a higher sensitivity and therefore, cannot 
be considered as markers for detecting PCa, it is of interest that concentrations of 
AA at the time of radical prostatectomy (RP), can predict biochemical recurrence 
(BCR) after surgery, thus suggesting a potential prognostic role for this metabolite 
in serum.
In order to get an insight into the proteins of the arachidonic acid pathway and 
their relationship with PCa, as well as their role in prognosis and prognosis, 
we performed a global proteomics analysis of PCa tissue. To accomplish this 
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aim, we first analysed differentially expressed proteins in PCa tissue compared 
to normal adjacent tissue (NAP). Next, we used both normalised intensities 
and expression intensities from a PCa tissue microarray (TMA), to identify 
prognostic properties for two de-regulated proteins: Anterior Gradient 2 (AGR2) 
and 15-LOX-B. Finally, we mapped the proteins of the AA pathway into the 
identified and quantified proteins in PCa tissue to obtain a simplified picture of 
the enzymes of the AA and their de-regulation in PCa. 
The results obtained in Chapters 3 and 4, highlighted the role of arachidonic 
acid, fatty acid metabolism and eicosanoid signalling in PCa. We decided 
to analyse the mass spectrometry ionisation of fatty acids by the addition of 
inorganic ions, in order to improve the analysis of these kinds of molecules by 
mass spectrometry. In Chapter 5, we present a mass spectrometry-based study 
of the incorporation of carboxylate-substituted super-halogens in the structural 
characterization of fatty acids by MS. We analysed the addition of Calcium ions 
in the fragmentation of arachidonic acid and the analysis of each unsaturation 
on the carbon chain. We proposed this novel technology as a useful tool in the 
analysis of fatty acids, because it allows a better identification of functional 
groups in fatty acids, steroids, complex lipids, and other metabolites also 
possible associated to PCa.
Finally, the findings are summarised and a general discussion is presented.
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Tryptophan (Trp) is an essential amino acid in humans that plays an important 
role in protein synthesis and it is a precursor of many biologically active 
metabolites, including kynurenine (Kyn)(1). The enzyme that converts 
tryptophan into kynurenine is indoleamine 2,3- dioxygenase (IDO), which has 
been associated to immune escape of tumour cells (2). Kynurenine was part 
of a subset of six metabolites found to be associated to prostate cancer (PCa) 
progression as described by Srekumar et al. (3) in plasma, urine and tissue. 
More recently, Kyn was proposed by McDunn et al. (4), as a metabolite that 
strongly correlates with aggressiveness of this malignancy as measured by 
Gleason scores. We determined concentrations of Kyn and Trp by fluorescence 
detection in serum samples from patients diagnosed with PCa, and classified in 
two groups: Gleason score 6 (n=15) and Gleason score 7 or higher (n=28). We 
compared these concentrations with the ones in a group of male subjects with 
low PSA levels and without PCa, denominated as PCa Controls (n=20). Power 
analysis indicated that these number of samples resulted in 70% of power with 
95% confidence and with effect size of 0.8 according to Cohen’s suggestions (5). 
Serum samples from patients diagnosed with colorectal liver metastases (n=10), 
liver adenoma (n=8), and hepatocellular carcinoma (n=6), as well as serum 
samples from healthy kidney donors (n=12), were also included as extra groups 
to generate information about tumour specificity. The use of serum samples for 
research purposes was approved by the Erasmus MC Medical Ethics Committee 
according to the medical research involving human subjects Act (MEC-ERSPC).
Serum samples were obtained according to the protocols reported by the 
Rotterdam Centre for the European Randomized Study of Screening for 
Prostate Centre (ERSPC)(6), and were stored at -80°C until further processing. 
Sample preparation included thawing of the samples on ice for 1 h, protein 
precipitation/dilution with trichloroacetic acid at room temperature, and 
centrifugation at 14.000 g at 4°C for 15 min. Kyn and Trp in the supernatant 
were separated by liquid chromatography (LC) and detected by fluorescence 
(FLD) using the standard addition method. This method is used to avoid matrix 
interferences by means of the addition of known quantities of the analyte of 
interest, with a concomitant increment in signal response of the instrument. We 
used zinc-mediated fluorescence for the accurate determination of Kyn (7, 8), 
and endogenous concentrations of Trp and Kyn were calculated by extrapolation 
using at least four points in a calibration curve (9). In all cases, the percentage of 
error was less than 15%, indicating that the small variances in the measurements 
allow differentiation between cases and controls. Stability was evaluated 
by consecutive measurements of pooled serum obtained from ten healthy 
individuals and also of the same pooled serum spiked with known amounts of 
Kyn and Trp to produce high, medium and low concentrations. Measurements 
were performed within a period of 20 h, which is the time the samples are stored 
in the autosampler before analysis. In all cases, relative standard deviations 
were lower than 5%. 
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Clinical-pathological characteristics of the patients involved in this study are 
presented in Table 1.
Table 1. Clinical and pathological characteristics of cases and controls. PCa 
Controls, PCa Patients.
Characteristic
Controls/
ERSPC
PCa Patients
(n=20) (n=43)
Age (years) Median 68.2 65.3
Range 58.2-69.4 56.2-69.1
PSA (ng/mL) Median 0.2 5.4
Range 0.1-4.4 2.0-15.1
Pathological 
State
n (%) n (%)
pT1 - 5(11.6)
pT2 - 27(62.8)
pT3 - 6(13.9)
pT4 - 4(9.3)
Unknown - 1(2.3)
Gleason 
Score
3+3 - 15(34.9)
3+4 - 21(48.8)
3+5 - 1(2.3)
4+3 - 4(9.3)
4+4 - 2(4.6)
Mean serum concentrations of Kyn for PCa patients were found at 2.1 ± 0.7 µM 
(mean ± SD) in Gleason 6, and 1.91 ± 1.2 µM in Gleason 7; these concentrations 
were not statistically different compared to the Control group (2.1 ± 0.7 µM). 
These values are consistent with reported data using different analytical 
approaches in healthy individuals (10). Trp concentrations for the PCa patients 
were also not significantly different (73.0 ± 13.8 µM for Gleason 6 and 70.7 ± 16.8 
µM for Gleason 7) compared to those for the Control group (77.7 ± 21.7 µM). 
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Mean concentrations of Trp and Kyn, as well as the calculated Kyn/Trp ratio are 
shown in Figure 1a-c. Differences among groups were not significant (p>0.05). 
Possible associations between metabolites concentrations in the serum of the 
PCa patients and clinical information available such as pathological stage and 
Gleason Score indicated no statistical significance (p>0.05). Our data show that 
there are no major alterations in extracellular concentrations of Trp and Kyn. 
Therefore, these parameters or the calculated Kyn/Trp ratio, have no potential 
as biomarker for the diagnosis of prostate cancer in serum.
Metabolic signatures between PCa tissue and benign prostate tissue have 
suggested that an increment exists in the concentration of Kyn in PCa tissue (3, 
4).  Although the number of serum samples used in this study was relatively 
small, the results presented here indicate that the reported metabolic signatures 
do not translate to changes in serum. Therefore, although metabolic alterations 
in kynurenine pathway might be occurring at the level of the prostate, this 
pathway cannot be considered as a target for serum biomarkers and of clinical 
applicability.
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Figure 1. Serum concentrations of a) Tryptophan, b) Kynurenine and c) Kyn/
Trp ratio in PCa Controls, PCa Patients Gleason 6 (n=15) and Gleason 7&8 
(n=28), HKD: Healthy Kidney Donors (n=12, median age: 57,2 years) , LA: 
Liver Adenoma (n=8, median age: 33.8), HCC: Hepatocarcinoma (n=6, medi-
an age: 56.3), and LM: Liver Metastasis (n=10, median age: 64.2).
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Abstract
Background: Arachidonic acid (AA) pathway has been shown to play a role 
in the development and progression of prostate cancer (PCa). In this study, we 
aimed to assess the changes in concentrations of hydroxyeicosatetraenoic acids 
(HETEs) in serum samples from patients diagnosed with PCa compared to 
controls.
Methods: HETEs were determined using ultrahigh pressure liquid 
chromatography-tandem mass spectrometry (UHPLC-MS/MS). 
Results: Elevated concentrations of 5-HETE, 8-HETE, 11-HETE and 15-HETE 
were observed in 6 out of 20 patients diagnosed with PCa; no statistical 
differences with controls were observed for 12-HETE and AA in the discovery set. 
An independent validation set composed of 222 samples divided in five groups 
ranging from subjects with low PSA and no PCa, to patients with advanced PCa 
was included. In 30% of the patients in the advanced PCa group, up to ten times 
higher concentrations of the same set of HETEs were observed with a significant 
concomitant decrease of the concentration of AA. Logistic regression and Kaplan 
Meier curves illustrate that a decreased concentration of AA is a predictor of PCa 
biochemical recurrence after radical prostatectomy (RP). 
Conclusions: From the present study, we conclude that a significant association 
between AA and AA metabolites in serum and PCa progression exists, although 
serum concentrations of HETEs exhibited low sensitivity towards the diagnosis 
of PCa. Analysis of RNA microarray data of PCa tissue indicate elevated levels 
of phospholipase A2, which might explain the elevated levels of HETEs and the 
significant decrease of AA in advanced PCa. 
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Introduction
Prostate cancer (PCa) is the second most common cancer in the Western world, 
and it has been predicted that around 70,000 men will die in 2013 from PCa in 
Europe (1). Identification of biochemical networks involved in PCa development 
and progression is helpful for the discovery of novel biomarker candidates, as 
well as for the establishment of new therapeutic strategies specially for early 
stages of the disease (2). 
The reported association of arachidonic acid (AA) metabolism with PCa 
indicates that there are various key routes within the AA pathway that can 
provide possible novel and therapeutic opportunities for treating PCa. Vainio 
et al. explored the expression patterns of 36 genes involved in AA pathway in 
approximately 10,000 human tissue samples and they found that six genes from 
this pathway, ALOX15B, CYP4F8, EPHX2, FAAH, PLA2G2A and PLA2G7, were 
highly expressed in PCa samples compared to normal tissue (3).Interestingly, 
one of these genes, arachidonate 15 lipoxygenase type II, or ALOX15B, is a 
gene that encodes a member of the family of the lipoxygenases which converts 
exclusively AA to the eicosanoid 15-hydroxyeicosatetraenoic acid (15-HETE) (4). 
In the human being, eicosanoids are bioactive metabolites produced mainly from 
essential C20 fatty acids such as dihomo-w-linolenic (20:3(n-6)), arachidonic 
(20:4(n-6)) and eicosapentaenoic acid (20:5(n-3)) (5). These metabolites are 
obtained by the action of three oxygenated-type enzymes: lipoxygenases (LOX), 
cyclooxygenases (COX-1 and COX-2) and cytochrome P450. Prostaglandins, 
leukotrienes, thromboxanes and other oxygenated derivatives such as 
hydroxyeicosatetraenoic acids (HETEs) are known as biologically active 
eicosanoids (6, 7). 
Their important role in the pathogenesis of different human diseases, including 
inflammation and cancer has been well documented (6-10). Figure 1 schematically 
illustrates the eicosanoids produced in the AA metabolism, as well as some of 
the genes involved in this pathway.
To date, the relationship between AA and the development and progression of 
PCa has been addressed from different perspectives (6, 7, 12). Several studies 
have reported expression analysis of COX and LOX in PCa tissue, cell lines 
and animal models using RT-PCR and western blotting (6, 7). Recently, AA 
metabolites, and especially those produced by LOX-type oxygenases, have 
been proposed as a target for treating PCa after studying mRNA and protein 
expression of LOX and COX in androgen receptor dependent and independent 
cell lines, xenografts, and biopsy samples of primary tumours (13). In body 
fluids, determination of urinary concentrations of 12-HETE and 20-HETE have 
been reported for patients diagnosed with PCa and benign prostate hyperplasia 
(BPH) (14). However, knowledge on concentrations of HETEs in serum and its 
association with PCa is still missing.  
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Figure 1. Arachidonic acid pathway. Arachidonic acid is released from 
phospholipids in the cell membrane by phospholipase A2 enzymes. Next, 
it is metabolised by one of three major routes: the cycloxygenase (COX), 
the lipoxygenase (LOX) and the cytochrome P450 epoxygenase route in the 
generation of eicosanoids. Grey circles indicate names of some of the RNA 
transcripts analysed in this study. Figure freely adapted from references (7, 
11).
In this study, we used ultra-high performance liquid chromatography coupled 
to tandem mass spectrometry (UHPLC-MS/MS) to compare serum concentra-
tions of AA and HETEs between patients diagnosed with PCa and controls. We 
report for the first-time serum levels of AA and HETEs in PCa patients at dif-
ferent stages of disease. We conclude that AA serum levels predict biochemical 
recurrence of PCa after radical prostatectomy.
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Clinical samples
Serum samples: Serum samples were collected at time of diagnosis. The discovery 
set included two sets of serum samples corresponding to patients diagnosed with 
PCa (n=20) and subjects with PSA values lower than 3.2 ng/mL denominated 
as < PSA Controls (n=20). Samples were obtained from men included in the 
Rotterdam Center for the European Randomized Study of Screening for Prostate 
Center (ERSPC). Samples were supplied by the Urology department, Erasmus 
MC, Rotterdam. Four sets of sera from patients diagnosed with colorectal liver 
metastases (n=10), liver adenoma (n=8), hepatocellular carcinoma (n=6) and 
healthy kidney controls (n=12), were also included in the discovery set. These 
samples were supplied by the department of Surgery of Erasmus MC, Rotterdam. 
The validation set included five groups of samples of prostate cancer patients 
at different stages of the disease. Serum samples were collected between 1994 
and 1998 and completed clinical follow up information was available for those 
patients within a period of 10 years. Subjects with low PSA values (≤1.0 ng/
mL) and no evidence of PCa after 9 years of follow up (n=44) were classified in 
group 1. Subjects with PSA values between 3-10 ng/mL, and repeated negative 
biopsies confirming no PCa (n=45) were included in group 2. Patients who were 
diagnosed with insignificant PCa, T1c & T2 and Gleason Score 6 (n=73), and 
underwent radical prostatectomy and were diagnosed with insignificant PCa, 
T1c & T2 and Gleason Score 6 (n=73) were classified in group 3. Patients with 
significant PCa (T2&T3a/b, Gleason 6&7 and tumour volume > 0.5 mL) and 
no PSA recurrence after radical prostatectomy, (n=41) were part of group 4. 
Patients with significant PCa (T2&T3a/b and Gleason 6&7) and PSA recurrence 
after radical prostatectomy, (n=19) were included in group 5. These samples 
were supplied by the Urology department, Erasmus MC, and were collected 
at the time of diagnosis for Groups 3-5. Status of the disease was histologically 
evaluated by an uropathologist of the Erasmus MC department of Pathology. All 
samples were collected and immediately stored at -80ºC until further analysis. 
Clinical pathological information of these patients is listed in Table 1. 
Chemicals: Arachidonic Acid, (S)-HETE HPLC mixture containing 5(S)-HETE, 
8(S)-HETE, 11(S)-HETE, 12(S)-HETE, and 15(S)-HETE, Arachidonic Acid-d8 and 
15(S)-HETE- d8 were purchased from Bio-Connect (Huissen, the Netherlands). 
All solvents used were obtained from commercial sources and were of LC-MS 
grade (Biosolve, Valkenswaard, The Netherlands). Most stock solutions were 
prepared by dissolving the substances in ethanol.
LC-MS/MS
The UHPLC used in this study was an automated Dionex Ultimate 3000 
(Thermo Fisher Scientific, Amsterdam, the Netherlands) system coupled to an 
API4000 triple quadrupole mass spectrometer (Applied Biosystems, Foster City, 
CA, USA) equipped with a Turbo Ion Spray electrospray ionization (ESI) source. 
Materials and Methods
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Table 1. Patient clinical and pathological characteristics. Discovery set 
included <PSA Controls, PCa Patients, HKD: Healthy Kidney Donors, LA: 
Liver Adenoma, HCC: Hepatocarcinoma, and LM: Liver Metastasis. Validation 
set included five groups of Prostate Cancer at different stages of the disease. 
Discovery < PSA 
Controls
PCa 
Patients
HKD LA HCC LM
(n=20) (n=20) (n=12) (n=8) (n=6) (n=10)
Age (years)
Median 61.8 67.1 57.2 33.8 56.3 64.2
Range 58.8-70.8 59.7-74.4 34.2-75.3 23.1-76.8 20.4-70.8 43.1-81.4
PSA 
(ng/mL)
Median 1.1 3.4
95% C.I. 1.0-1.8 2.2-8.4
Pathological 
State
n(%) n(%)
pT1 - 9(45)
pT2 - 4(20)
pT3 - 2(10)
PT4 - -
Unknown - 5(25)
Experiments were performed using Selective Reaction Monitoring (SRM) in ion 
negative mode. Source-dependent mass spectrometer (MS) parameters were set 
at 20 psi for curtain gas, -4000 V for Ion Spray Voltage and 500°C for ion source 
temperature. Nebulizer 1 and 2 were kept at 20 psi. Compound-dependent MS 
parameters are given in Supp. Table 1. Chromatographic separation was carried 
out on a Kynetex analytical column (100 x 2.1 mm, 1.7 µm particle size) from 
Phenomenex (Aschaffenburg, Germany) at 40°C. Gradient elution conditions 
were optimized using 0.1% formic acid (FA) in water as solvent A, and 0.1% 
FA in ACN as solvent B. The analysis time for each sample was 8 min. Data 
acquisition and peak integration was performed using Analyst software version 
1.4.2 (Applied Biosystems, Foster City, CA, USA). Representative chromatogram 
of the simultaneous determination of AA and HETEs in serum is shown in Supp. 
Fig 1.
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Validation
Group 1 Group 2 Group 3 Group 4 Group 5
(n=44) (n=45) (n=73) (n=41) (n=19)
Age (years)
Median 59.6 62.1 63.4 64.9 65.6
Range 54.6-66.8 55.1-66.8 55.0-72.8 55.7-70.4 48.7-71.1
PSA (ng/mL)
Median 0.5 4.6 4.2 4.7 17.6
95% C.I. 0.4-0.6 4.6-5.8 4.3-5.6 4.7-8.9 10.0-25.1
Pathological 
State
n(%) n(%)  n(%) n(%) n(%)
pT1 - - 51(68.9) 19(46.3) 2(10.5)
pT2 - - 23(31.1) 20(48.8) 7(36.8)
pT3 - - - 2(4.9) 6(31.6)
pT4 - - - - 1(5.3)
Unknown - - - - 3(15.8)
Gleason 
Score
6 - - 73(100) 25(61.0)
7 - - - 16(39.0) 12(63.1)
8 - - - - 1(5.3)
9 - - - - 1(5.3)
Unknown - - - - 5(26.3)
Sample preparation
 Serum samples were thawed on ice for 2 hours and 20 µL were immediately 
transferred to a new Eppendorf cup and were spiked with internal standards. 
For protein precipitation, cold methanol (-20°C) was used. After centrifugation 
at 14,000 x g for 10 min, 20 µL of the supernatant were diluted with the mobile 
phase solvents and injected for UHPLC-MS/MS analysis. 
Statistical Analysis
Statistical calculations were performed with GraphPad Prism 5 for Windows 
(GraphPad Software Inc., La Jolla, CA, USA) and SPSS version 20.0.0.1 (IBM 
Corp., Armonk, NY, USA).
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We decided to include another group of patients diagnosed with other 
malignancies in order to test the possible specificity of HETEs towards PCa. 
Median concentrations of HETEs in patients diagnosed with hepatocarcinoma 
(HCC), liver metastasis (LM), liver adenoma (LA), and health kidney donors 
(HKD), are presented in Figure 2. For none of the HETEs studied and for AA, 
a statistical difference among these groups was observed. High concentrations 
of HETEs compared to the median values in all the groups in the discovery set 
were found in one patient diagnosed with HCC, however these concentrations 
are up to five times lower compared to the highest concentrations found in PCa 
patients.
The variables evaluated were age, serum concentrations of AA, 5-HETE, 8-HETE, 
11-HETE, 12-HETE and 15-HETE, PSA at the time of diagnosis, prostate volume, 
pathological status, and Gleason Score. Pearson r2 or Spearman’s correlation was 
performed to evaluate associations between concentration of HETEs, AA, PSA 
level, Gleason Score or pathological stage. Comparison of biomarkers median 
values between PCa patients and PCa controls in the discovery set was performed 
by Mann-Whitney U test. The same test was used to analyse biomarkers within 
the groups in the validation set. Kruskal-Wallis test was performed to evaluate 
differences among the additional group of cancer patients, as well as among 
the PCa patients in different groups in the validation set. Combined predictive 
effect of HETEs or AA was addressed by logistic regression. Kaplan-Meier (KM) 
curves were constructed to assess PSA recurrence as a function of time after RP, 
and log-rank test was used to evaluate differences between curves. In this two-
tailed test, a p value of < 0.05 was considered significant.
Concentrations of HETEs are elevated in a sub-group of PCa patients
Clinical and pathological characteristics of patients in this study are summarized 
in Table 1. Median concentrations of HETEs in the discovery set composed of 
prostate controls and PCa patients are described in Fig. 2. In 6 out of 20 PCa 
patients (33%), concentrations up to ten times higher than controls were found for 
5-HETE, 8-HETE, 11-HETE and 15-HETE with a significant difference between 
controls and PCa patients for 5-HETE (p=0.0090). The selected sub-group of 
patients with elevated concentrations of HETEs exhibited the same trend in all the 
HETEs studied except for 12-HETE and AA. No significant associations between 
HETEs or AA concentration and pathological stage were found, but at least 4 of 
the patients in this sub-group exhibited pathological stage T2a or T3a. In Supp. 
Table 2, concentrations of HETEs and AA in the discovery set are presented. The 
sub-group of patients with relative extreme elevated concentration of HETEs is 
included in a different column in the same table for separate analysis.
Results
Arachidonic acid metabolites in serum from PCa patients
51
HETEs and AA are associated with advanced stages in PCa
Concentrations of HETEs were measured in an extended group of subjects 
without PCa and PCa patients at different stages of the disease to evaluate 
prognostic properties. Serum HETEs concentrations in the five groups evaluated 
are presented in Figure 3. Groups were classified according to PSA values and 
pathological status. In group 1, subjects with PSA values lower than 1.0 ng/
mL and no evidence of PCa after more than 9 years of follow up were included. 
In this group, the median PSA value was 0.5 ng/mL and no correlations were 
found between concentrations of HETEs or AA and PSA values or age at the 
time of sampling. Group 2 included subjects with abnormal PSA values but 
repetitive negative biopsies for PCa. One subject in group 2 exhibited high levels 
of HETEs, but PCa was not detected in the 9 years following the sampling of 
the serum. Taking into account that clinical follow up indicated that subjects in 
groups 1&2 did not show evidence of PCa, these two groups were considered 
as controls and grouped for further analysis. In group 3 were included patients 
with insignificant PCa, and the median PSA value was 4.2 ng/mL. There were 
no statistically significant differences with respect to concentrations of HETEs 
and AA between groups 1&2 and group 3, thus confirming the results obtained 
in the discovery set. 
Group 4, composed of patients with pathological stage T2 & T3a/b and a 
tumour volume higher than 0.5 mL, represents an advanced stage of the disease. 
However, clinical follow up within at least five years after RP indicated no 
recurrence. In this group, median PSA value was found as 4.7 ng/mL and no 
statistical differences were found in the comparison between groups 3 and 4, 
and between groups 1&2 and 4. Similarly to the PCa patients in the discovery 
set, high concentrations of 5-HETE, 8-HETE, 11-HETE and 15-HETE were found 
in 4 out of 41 patients (10%) in group 4.
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Figure 2. Serum concentrations of eicosanoids in the Discovery Set. Elevated 
concentrations of 5-HETE, 8-HETE, 11-HETE and 15-HETE are observed in 6 
out of 20 PCa patients. Patients diagnosed with other malignancies are also 
included to analyse specificity of the markers towards PCa. HKD: Healthy 
Kidney Donors, LA: Liver Adenoma, HCC: Hepatocarcinoma, and LM: Liver 
Metastasis patients were included in the discovery set.
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Patients with the most advanced PCa status, defined as Gleason score equal or 
higher than 7 and detectable PSA levels after three months after RP, represented 
group 5. High concentrations of 5-HETE, 8-HETE, 11-HETE and 15-HETE were 
found in 6 out of 19 (32%) of the patients in group 5, and as a consequence, a 
significant difference was observed between group 3 and 5 for the HETEs. In 
Figure 3, concentrations of HETEs and AA in the validation set are presented 
and a clear trend showing that the concentration of HETEs increases with the 
status of PCa is observed (although this behaviour is seen in less than 35% of 
the cases under study). Concentrations of AA in group 5 were found up to 5 
times lower compared to all the groups under study including the controls and 
this effect showed a significant difference between these groups (p<0.0001). In 
addition, a Kruskal-Wallis analysis for AA in the five groups, too, indicated a 
significant difference among them (H=38.02, p<0.0001). 
Logistic Regression confirms serum concentration of AA at the time of diagnosis as a 
predictor of PSA recurrence after radical prostatectomy
Logistic regression confirmed the negative relationship between the concentration 
of AA and the PSA recurrence after 10 years’ follow-up in the PCa patients who 
were treated by radical prostatectomy. Analysis was performed for patients 
in groups 3, 4 and 5, using backward selection. Age, PSA, Gleason Score, and 
concentration of HETEs and AA were considered as independent variables. 
Results indicated that the significant variables were PSA, Gleason Score, and 
AA. However, ROC analysis indicated a small reduction in the AUC when AA 
is added to the model (0.751 vs. 0.792). The Logistic Regression Model’s results 
are presented in Table 2.
Sample Variables in the final 
model
Odds 
ratio
95 % C.I. AUC
Groups
3, 4 and 5
Intercept 0 0.792
PSA 1.087 1.05 - 1.17
Gleason Score 3.008 1.15 - 7.86
Groups
3, 4 and 5
Intercept 0.001 0.751
PSA 1.071 0.99 - 1.15
Gleason Score 2.231 0.80 - 6.17
AA 0.946 0.91 - 1.01 
Table 2. Logistic Regression Model.
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Figure 3. Serum concentrations of eicosanoids in the Validation Set. High 
concentration of HETEs are observed in 30% of the patients with the most 
advanced stage of PCa.
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PSA recurrence after radical prostatectomy and its relationship with serum HETEs and 
AA concentration
Kaplan-Meier (KM) curves were constructed to analyse PCa progression after 
radical prostatectomy as a consequence of biochemical recurrence of the disease 
(PSA recurrence). In these curves, the independent variable was set as the 
time when a rise in the PSA level was observed. Observations were censored 
at the last month of clinical follow up after RP. Figure 4a, shows KM curve 
of PSA recurrence for those patients in the validation set who exhibited high 
concentrations of HETEs (9 patients from groups 4&5). Although the number of 
patients with high concentrations of 5-HETE, 8-HETE, 11-HETE and 15-HETE is 
low compared to the whole group of patients, difference between the two curves 
indicates that this panel of HETEs may be considered as positive predictor of 
PSA recurrence (p=0.048). The same analysis was performed when the predictor 
factor is PSA at the time of diagnosis and the cut-off value is set as 4 ng/mL. 
Figure 4b shows KM curves for PSA recurrence after RP in groups 3, 4 and 5 
and a statistical significant difference was observed between the two curves 
(p=0.022).
In order to evaluate the effect of AA concentration as a predictor of PSA 
recurrence, a cut-off value was chosen according to a statistical descriptive 
analysis for AA concentrations in groups 3-5. Supp. Figure 2 shows KM 
curves for AA concentrations in the validation set at 25% percentile (9.2 ng/ 
µL, p=0.001), AA concentrations between 25-75% percentile (9.2-18.4 ng/µL, 
p=0.006, and AA concentrations in 75% percentile (18.4 ng/µL, p=0.934). Thus, 
cut-off value of 10 ng/µL was chosen and the same above-mentioned conditions 
for the independent variable were kept for the analysis. In Figure 4c, a KM curve 
of PSA recurrence as a function of time after surgery and AA concentration as 
a factor is presented. A statistical significant difference was observed when the 
curve of PSA progression in those patients with AA concentration lower than 
10 ng/µL, is compared to the curve for patients with AA concentrations higher 
than this cut-off value (p=0.0003). Therefore, AA concentrations lower than 10 
ng/µL at the time of diagnosis in PCa patients may be considered as potential 
positive predictor of PSA recurrence and a selective readout of PSA recurrence 
related to advanced disease. 
Figure 4d shows the PSA recurrence after surgery when combined effects of 
PSA level at diagnosis and AA concentrations were evaluated (blue line: AA 
concentration > 10 ng/µL, PSA level < 4 ng/mL, red line: AA concentration < 10 
ng/µL, PSA level > 4 ng/mL). A statistical significant difference was observed 
(p<0.0001) and the difference between the two lines was found to be even higher 
compared to Figure 4a-c. These results suggest that this non-invasive parameter 
aids in the prediction of PCa recurrence after RP.
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Time / Months
a.
p = 0.048
Time / Months
b.
p = 0.022
Time / Months
c.
p = 0.03
Time / Months
d.
p = 0.001
Figure 4. Kaplan-Meier curves assessing the probability of PSA recurrence 
in groups of patients with PCa discriminated by a: HETEs concentration b: 
PSA at the time of the diagnosis c: AA concentration and d: Combined AA 
concentration and PSA level, as a function of time after surgery in months. 
Blue lines represent: a: low concentration (< 5ng/µL) of HETEs, b: PSA < 4 
ng/mL, c: AA concentrations > 10 ng/µL, d: AA concentrations > 10 ng/µL 
and PSA level < 4 ng/mL. Red lines represent: a: high concentration (> 5ng/
µL) of HETEs, b: PSA levels > 4 ng/mL, c: AA concentrations < 10 ng/µL, and 
d: AA concentrations < 10 ng/ µL and PSA levels > 4 ng/mL.
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The aim of this work was to determine serum concentrations of HETEs and AA 
in PCa patients in order to evaluate the correlation with progress of disease. 
For that purpose, we decided to use a liquid chromatography-based technique 
because it allows specific, sensitive, reproducible and robust measurements (15), 
which are essential requirements for clinical applications. 
We have used an analytical method that allows the simultaneous measurement 
of HETEs in serum in 7 minutes and which can be organized in an automated 
way. Sample preparation was optimized to avoid expensive and relative time 
consuming procedures such as solid phase extraction (SPE). Thus, extraction 
with 4 volumes of cold methanol was chosen as the optimal condition in sample 
preparation for obtaining good linearity (R=0.95 or higher) and good repeatability 
within runs (<20 % CV). We decided to evaluate only five HETEs due to the 
availability of the stable isotope labelled standards. This methodology can be 
extended for further studies for the analysis for instance of ω-terminal HETEs 
due to the good peak resolution exhibited in the chromatographic profiles (Supp. 
Fig. 1). In the present study, we have analysed 76 samples in the discovery set 
and 222 samples in the validation set, in addition to the internal quality controls, 
and we have obtained coefficients of variation < 20% for the stable isotope 
compounds (15-HETE d8 and AA d8), as well as good reproducibility in retention 
time (<5%) and peak shape, indicating a high reliability of the measurements.
We designed the experiments with the aim to profile HETEs in serum samples 
from the Rotterdam section of the European Randomized Study of Screening 
for Prostate Cancer (ERSPC), and also included patients diagnosed with other 
malignancies in order to test specificity towards PCa. Results indicated that a 
selected subgroup of 6 patients in the discovery set exhibited high concentration 
of HETEs and two different patients also exhibited elevated concentrations of 
AA. Serum HETEs concentrations assessed for controls in both the discovery 
and validation set were found to be in the same order of magnitude as values 
reported in literature using different analytical approaches in metabolomics (16). 
We have not found significant differences among concentrations of 12-HETE in 
all the patients; however, this can be explained by the lack of selectivity of our 
method to differentiate the metabolite 12(S)-HETE to the optical isomer 12(R)-
HETE (17, 18). Further experiments are required to identify possible associations 
of each enantiomer with PCa and also the role of these two metabolites with the 
disease progression.  
Comparison of concentrations of HETEs and AA between the discovery set and 
validation set indicated similarity in median values in subjects categorised as 
Controls. A clear trend indicates an elevated concentration of HETEs as well 
as a reduced concentration of AA in patients with a more advanced stage of 
PCa (Group 5). We performed a logistic regression analysis and made Kaplan-
Meier curves for groups 3-5 to identify the role of these metabolites as predictors 
Discussion
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of PCa recurrence. We have identified that the AA concentration at the time of 
diagnosis is a negative predictor of PCa recurrence (expressed as an increase in 
PSA level after radical prostatectomy), and this non-invasive parameter can be a 
potential marker for biochemical recurrence; however, further and independent 
studies in extended cohorts, using different analytical methodologies, and with 
detailed evaluation towards specificity in the model are required to make it 
clinically applicable. We have observed that AA concentrations notably decrease 
in those patients with PSA recurrence (Group 5), but patients diagnosed also as 
an advanced status (Group 4) had similar concentrations even compared with 
the control groups (Groups 1&2). This makes difficult to propose any hypothesis 
about how AA is metabolised in PCa patients at the most aggressive stage, and 
how the AA metabolism in PCa cells may modify eicosanoids concentrations in 
serum. We have found that concentrations of 5-HETE, 8-HETE, 11-HETE and 
15-HETE were high in a selected group of patients having an advanced stage 
of PCa. It is known that 15-LOX-2 converts AA exclusively to 15-HPETE, which 
is further reduced by cellular peroxidases to 15-HETE (4). Therefore, a link 
between tissue mRNA expression and serum concentration of 15-HETE might 
exist, although this reasoning could be strongly affected by different clearance 
rates from blood for the various compounds studied and variations of clearance 
of these compounds among patients. Similarly, 5-LOX catalyses the first step in 
oxygenation of AA to produce 5-HPETE with subsequent production of 5-HETE 
and leukotriens. We have found a statistical significant increase of 5-HETE 
concentrations in PCa patients in the discovery set and in the patients with 
advanced in the validation set. Although the number of patients involved in this 
study is relatively small, these findings suggest that 5-HETE may be considered 
as a potential marker for PCa prognosis for further validation studies, in an 
extended cohort. Different researchers have reported overexpression of 5-LOX 
in PCa tissue, and they have also suggested that 5-LOX inhibitors participate in 
cell growth inhibition through the induction of apoptosis (6, 19-22), suggesting 
an important role of 5-LOX in PCa progression.
Serum concentrations of 12-HETE were not found to be high in the subgroup 
of patients with high concentration of the other HETEs determined. This 
metabolite was proposed recently as a potential marker for PCa progression in 
tissue (13), and high levels of platelet type (P-) 12-LOX mRNA in 40% of PCa 
tissue have also been reported (22). It suggests a crucial role of LOX-12 pathway 
in PCa. In our experiments, we cannot exclude the possibility that endogenous 
levels of 12-HETE might be also affected by the concentration of the optical 
isomer 12(R)-HETE because only a reverse-phase analytical column is used for 
the measurements. Therefore, further experiments validating the correlation 
of 12(S)-HETE and possible over-expression of LOX-12 in tissue have to be 
considered.
We also noticed high concentration of 8-HETE and 11-HETE in the selected 
subgroup of patients. It is known that AA can be metabolized also by 
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microsomal P450 monoxygenases (Cytochrome P450) by means of a Bis-allylic 
oxidation (lipoxygenase –like reaction) to generate 6 regioisomer HETEs, where 
the hydroxyl group is located at the positions 5, 8, 9, 11, 12 or 15 of the chain 
(23). We hypothesize that high concentration of HETEs may be related with 
the deregulation of phospholipases-type enzymes that release AA from the 
phospholipids in the cell membrane (Fig 1) (24). This hypothesis is supported by 
Schumacher et al. who demonstrated that AA levels in PCa tissue are decreased 
in comparison to NAP, thus suggesting that AA is metabolised preferably in PCa 
cells into pro-tumoural eicosanoids (25). 
To date, this relative large family of enzymes has been classified into six classes 
on the basis of their nucleotide and amino acid sequence homology as: sPLA2, 
cPLA2, iPLA2, PAF-AH, LPLA2 and AdPLA2, and more than 20 members have 
been identified in mammals (26). 
Association of the enzymes of the PLA2 family with PCa has been described 
in literature recently, and some of them have been proposed as alternative 
targets in the treatment of PCa (3, 27-30). Recent studies have confirmed that 
cytosolic phospholipase A2-α plays a role via AA and one of its metabolites, 
5-HETE in functioning of protein kinase B (AKT), extracellular signal-regulated 
kinase (ERK) and androgen receptor (AR) signalling in PTEN-null/mutated 
prostate cancer cells. These results support that inhibition of cPLA2-α could be 
an attractive and effective target for treating advanced PCa and also support the 
results obtained in this study indicating association of serum AA and HETEs 
and the progression of PCa. However further experiments in vivo or ex vivo 
have to be performed to analyse whether the production of eicosanoids, and 
especially the HETEs, is altered by the deregulation of the phospholipase-type 
enzymes.
We have analysed changes in the concentration of AA and HETEs in serum 
samples from PCa patients at different stages of the disease. High concentrations 
of HETEs and a reduction in the concentration of AA was observed in those 
patients having advanced and aggressive state of PCa. Decreased AA levels 
in serum predict biochemical recurrence for PCa, but large samples as well as 
complementary techniques are required for further validation and clinical use. 
The results shown here also highlight the relevance of studying the arachidonic 
acid pathway in PCa development and progression, and how it can be considered 
as an important target for therapeutic strategies.
Conclusions
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Abstract
Carboxylate substituted superhalogens of the type RCOOMX2− (M = Mg, Ca,Sr, Ba, Mn, Co, Ni, Zn and X = Cl, Br) are easily accessible in the gas-phase by 
electrospray ionization. Their collision induced dissociation (CID) characteristics 
have been probed using ion trap and triple quadrupole mass analyzers with 
particular emphasis on the behaviour of RCOOCaCl2− type ions.  In the iontrap these appear to readily react with residual water yielding HOCaCl2− as the
hydrolysis product. In the absence of water, a collision induced McLafferty type
rearrangement takes over to produce HCaCl2− with the expulsion of an olefinand CO2. A brief computational analysis using the CBS-QB3 model chemistry provides a satisfactory rationale for these observations.
When complexed with MX2 (M = Mg, Ca, Sr, Ba) long chain unsaturated aliphatic carboxylate anions undergo various backbone cleavages upon collision. These 
leads to structure diagnostic olefin losses because the position of the double
bonds remains intact. Such cleavages are absent in the bare ion RCOO−. 
The long chain ions RCOOMX2− also produce the intriguing species [CO2]MX2−•.These were characterized by CID experiments while theory indicates that they 
may be viewed as a CO2 molecule captured by the salt anion MX2−•.Finally, it is shown that the CID spectra of RCOOCaCl2− ions derived fromall-trans retinoic acid, a compound of current interest in biochemistry and 
medicine, shows a unique structure diagnostic dissociation that may greatly aid 
its qualitative and quantitative analysis.
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Introduction
In 1981, Gutsev and Boldyrev introduced the term “superhalogen” to describe 
complex radicals like BF4• and AlF4•, which have a comparatively high Electron 
Affinity (EA), higher than that of the parent halogen atom (1). Superhalogens 
have the formula MXk+1, where M is a metal atom with maximum valence k while X is a halogen atom. The vertical detachment energy (VDE) of an [MXk+1] − anion greatly exceeds that of the corresponding halogen anion (2). For example, 
the VDE of CaCl3− (6.62 eV) (3) is much larger than the EA of Cl• (3.617 eV)(4). Superhalogens are promising candidates for oxidizing species with a 
high ionization energy (such as O2 and Xe) and for the preparation of organic superconductors (5).  Moreover, they allow the synthesis of new classes of ionic 
compounds like Xe+[PtF6] − (6).The presence of halogen atoms in superhalogens is not mandatory (7). Many 
other functional groups may serve as ligands in superhalogen anions (8, 9). This 
concept has been used to render otherwise electronically unstable anions stable. 
For example, whereas the EA of C2H5− is negative ( 0.263 ± 0.089 eV), the VDE of [C2H5MgF2]− is positive (4.088 eV)(10) and very much so. Theoretical calculations have shown that electrophilic substituents, such as 
COOH, too, may lead to species having a large VDE, for example the VDE of 
Mg(COOH)3− has been calculated at 5.2 eV (8). 
It occurred to us that carboxylate anions (RCOO−) could also serve as suitable 
ligands to produce superhalogens of the type RCOOMX2− (M = Mg, Ca, Sr, Ba, Mn, Co, Ni, Zn, X = Cl, Br) and that such species may be accessible by 
Electrospray Ionization (ESI). Since RCOO• radicals have relatively large EAs 
(for example the EA of CH3COO• is 3.496 ± 0.0010 eV(4), on a par with the EA of Cl•), it may reasonably be expected that RCOOMX2− anions, too, will have large VDEs. Thus, in RCOOMX2−, the electron may well be sufficiently bound to allow unimolecular or collision induced dissociations to take place below the 
threshold for electron detachment. 
This indeed is the case: in the course of this study we observed structure 
characteristic dissociations of long chain unsaturated fatty acids substituted by 
superhalogen groups. We also discovered novel species, like the radical anion 
[CO2]CaCl2−•, whose structure we probed by ab initio calculations.The RCOOMX2− ion can also be viewed as a RCOO− anion to which a salt molecule MX2 is attached, that is as a carboxylate anion/salt complex. While preparing this contribution, the groups of R.A.J. O’Hair and J-C. Tabet 
reported(11) a comprehensive study that deals with the dissociation chemistry 
of organomagnesates [RMgX2]− generated  by decarboxylation of  [RCO2MgX2]−. Their results will be discussed where they overlap with ours.
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Experimental Section and Computational 
Methods
Experiments
Collision induced dissociation (CID) experiments were performed using a 
Bruker Esquire ESI-ion trap mass spectrometer. A crucial parameter is the 
capillary current: it has to be kept below 30 nA to prevent destruction of the 
metal complexes. CID experiments were also performed on an AB Sciex API 
4000 triple quadrupole mass spectrometer with the following conditions: 
declustering potential 20V, entrance potential 10V, collision exit potential 12V, 
capillary voltage 5000V. Comparing ion trap and triple quadrupole results 
allows the identification of ion-molecule reactions that take place with residual
water molecules present in the ion trap.
FT-ICR measurements were performed on a Varian 9.4T Fourier Transform Ion 
Cyclotron Resonance mass spectrometer operated in the positive electrospray 
mode, at a resolution of 30 000 (FWHM at m/z 150). The RCOOMX2− ions weregenerated as described below, isolated in the ICR cell and then dissociated by 
sustained off–resonance irradiation collision-induced dissociation (SORI-CID).
The RCOOMX2− complexes were generated as follows. A 10 μL 0.01 M RCOOH
solution in water or ethanol was mixed with 10 μL of a 0.05 M solution of the
salt MX2 in water. This mixture was diluted with 200 μL of isopropanol/water
(1:1) and then infused into the MS at a rate of 240 μL/hr. The observed anions
RCOOMX2− were then mass selected and subjected to CID experiments.
Theoretical calculations
The calculations were performed with the CBS-QB3 model chemistry (12) using 
the Gaussian 09, Rev C.01 suite of programs (13) on the SHARCNET computer 
network at McMaster University. All relative energies presented in the text and 
in the energy diagram are derived from CBS-QB3 total enthalpies (298 K) in 
kJmol-1. The complete set of computational results is available from the authors 
upon request.
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Results and Discussion
Formic acid and acetic acid:  unimolecular decay versus hydrolysis
Table 1 shows the neutral losses observed for HCOOMCl2− and CH3COOMCl2− (M = Ca, Mn, Zn). It is seen that for the formate anion, the CaCl2 adduct eliminates CO, via a putative 1,2-H shift, whereas the MnCl2 and ZnCl2 adducts decarboxylate, via a 1,3-H shift.
Table 2 shows the Hydride Ion Affinities (HIA) and OH− affinities (in kJmol-1) of 
Ca2+ and Zn2+ calculated by the CBS-QB3 method. It follows that Ca2+ prefers to 
attach OH− over the binding of H−, but the reverse is true for Zn2+. This would 
rationalize the observed difference in behaviour, namely that HCOOCaCl2
− 
decarbonylates to produce HOCaCl2−, whereas HCOOZnCl2− decarboxylates to form HZnCl2−.
Table 1. Reactions observed for HCOOMCl2− and CH3COOMCl2−
M HCOOMCl2− CH3COOMCl2−
Ca - CO - CH2CO
Mn - CO2 - CO2
Zn - CO2 - CO2
Table 2. Hydride Ion Affinity (HIA) and OH− affinity of Ca2+ and Zn2+ (CBS-
QB3, kJmol-1).
Metal 
ion
HIA OH− affinity
Ca2+ 1275 1390
Zn2+ 1860 1780
However, deuterium labelling experiments indicate that formation of HOCaCl2− may not be a unimolecular process. Ions DCO2CaCl2− and CD3CO2CaCl2− both form HOCaCl2− to the exclusion of DOCaCl2−.  A possible explanation is that initially DOCaCl2− is formed by decarbonylation and that it undergoes a rapid H/D exchange with residual water in the ion trap. However, ions HOCaCl2− dominate the ion trap CID spectrum of various RCOOCaCl2− anions, including that of C6F5COOCaCl2−, which has no H atom available for a unimolecular decarbonylation. This leads us to propose that the product ion HOCaCl2− actually results from the following hydrolysis reaction with residual water present in the 
ion trap:   
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RCOOCaCl2−  +  H2O              RCOOH  +  HOCaCl2− … (1) 
This hydrolysis reaction is discussed in more detail in the next section. Hydrolysis 
was also observed in the study of reference 10; for example, PhCH2CH2MgCl2− abundantly forms m/z 111, HOMgCl2−. 
Propanoic acid
The ion trap CID mass spectrum of CH3CH2COOCaCl2− presented in Figure 1a displays an intense peak for formation of HOCaCl2− at m/z 127. As stated above, this product ion could be due to a unimolecular process, most likely a 1,4-H shift 
followed by the losses of C2H4 and CO (eq. 2) or it could result from a hydrolysis reaction, (eq. 3):
       CH3CH2COOCaCl2−              CH2=CH2  +  CO     +   HOCaCl2− …….. (2)
CH3CH2COOCaCl2−   +   H2O                CH3CH2COOH       +    HOCaCl2− …….. (3)
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Figure 1. CID mass spectra of CH3CH2COOCaCl2− obtained on an ion trap (a) 
and on a triple quadrupole CID mass spectrometer (b).
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The CID mass spectrum as recorded on the triple quadrupole is shown in Figure 
1b. It is seen that additional reactions appear, viz. formation of Cl− (loss of 
CH3CH2COOCaCl) and formation of HCaCl2−. That Cl− is not seen in the ion trap 
spectrum is because this fragment lies below the mass cutoff (m/z 50). However, 
another important fragment that is observed in Figure 1b but not in Figure 
1a is HCaCl2−, m/z 111; its formation probably proceeds via a unimolecular 
McLafferty type rearrange-ment, via a 1,5-H shift, eq. (4):
CH3CH2COOCaCl2−             CH2=CH2   +   CO2   +   HCaCl2− …… (4)
This raises the question why HCaCl2− is not observed in the ion trap.The results of our model chemistry calculations for reactions 2, 3 and 4 are 
presented in Figure 2. In the presence of water, reaction (3) is the least energy 
demanding reaction and this hydrolysis reaction, we propose, occurs in the ion 
trap. In the absence of water (or if the reaction time is significantly smaller as 
in the triple quadrupole apparatus) reactions (2) and (4) should take over, as 
indeed is observed, see Figure 1(b). Thus, the fragment ion HOCaCl2− observed in the ion trap is due to hydrolysis, but in the triple quadrupole it is the result of 
a unimolecular reaction. Other reactions that are seen at these elevated internal 
energies are loss of CO2 to produce the organometallate CH3CH2CaCl2− and loss of CaCl2.
Figure 2. Energy diagram for hydrolysis and dissociation reactions of 
CH3CH2COOCaCl2−.
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The ion CH3CH2COOZnCl2− was also investigated and it showed, both in the ion trap and in the triple quadrupole apparatus, loss of CO2 paralleling the behaviour of the formate and acetate complex ions, see above. Thus, the zinc analogue 
does not undergo hydrolysis in the ion trap but it forms an organometallate via 
decarboxylation(14).
Long chain aliphatic acids
Long chain saturated aliphatic acids show only one or two dissociation reactions 
when their deprotonated forms are complexed with CaCl2 and ZnCl2 and are then subjected to CID in the ion trap. Thus, the stearic acid ion C18H35COOCaCl2− generates only HOCaCl2− probably via hydrolysis whereas the zinc analogue loses CO2 and ZnCl2. However, when an unsaturation is present, such as in linoleic acid, backbone dissociations are observed for the CaCl2 complex but not for the ZnCl2 complex. An example is provided by the species derived from arachidonic acid, C20:4. The bare carboxylate anion itself, C20H31COO−, predominantly undergoes decarboxylation. This is not a structure characteristic 
dissociation as many long chain carboxylate anions lose CO2. However, when 
CaCl2 is attached to the arachidonic anion, a very different situation obtains. Figure 3a shows many odd mass, even electron fragments that correspond 
to backbone dissociations via olefin losses. Thus, the intense fragment ion at 
m/z 181 could be CH2=CH-COOCaCl2− produced by a hydrogen shift and C-C 
cleavage β to the double bond.
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Figure 3. (a) CID mass spectrum of the arachidonic carboxylate anion 
complexed with CaCl2 on an ion trap; (b) arachidonic d8 carboxylate anion on 
an ion trap; (c) arachidonic carboxylate anion on a triple quadrupole.
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The ion trap CID mass spectrum of C20H23D8COOCaCl2− derived from arachidonic acid-d8 where all deuterium atoms are at the double bonds, is shown in Figure 
3b. It is seen that the masses of the backbone fragments shift by the number of 
deuterium atoms present in the fragment ion.
A similar situation pertains to stearidonic acid C18:4 where backbone fragments 
are seen for β- cleavages. The observed backbone fragments for the stearidonic 
and arachidic complexes are listed in Table 3 to show that the observed fragment 
masses follow the double bond positions. These are prime examples of charge-
remote fragmentations, which have been extensively studied by Gross (15-17) 
and others (18).
Arachidonic acid is an essential fatty acid that cannot be synthesised de novo. It 
is a component of the phospholipids of cells and it favours membrane fluidity 
due to the four double-cis bonds of its structure (19, 20). In body fluids, levels 
of arachidonic acid are measured by LC-MS/MS in the negative ion mode, 
but as mentioned above, the carboxylate anion dissociates by a non-structure 
characteristic loss of CO2. However, when MX2 (M = Mg, Ca, Sr, Ba, X = Cl, Br) is attached to the anion, highly structure characteristic backbone cleavages 
are seen. For the transition metal ions Mn – Zn, much simpler spectra are 
obtained: formation of MCl2−•, HMCl2− and loss of CO2 is observed but backbone fragmentations do not occur.
Stearidonic acid Arachidonic acid
Double 
bond
Observed fragment 
masses (m/z)
Double 
bond
Observed fragment 
masses (m/z)
6 237 5 223
9 277 8 263
12 289 11 275
15 329 14 315
Table 3. Double bond positions and observed fragment masses for C18H27COO-CaCl2− and C20H31COOCaCl2− derived from stearidonic and arachidonic acid.
We note that the CID mass spectrum of Figure 3c recorded on the triple 
quadrupole instrument shows an intense peak for m/z 111, HCaCl2−, which is absent in the ion trap mass spectrum of  Figure 3a. This is because the mass 
cutoff in the spectrum of Figure 3a lies at m/z 112 and so ions below this mass 
are not detected by the ion trap.
We were surprised to find two odd electron species in the CID mass spectra of 
Figure  3, namely at m/z 154 and at m/z 168 and will briefly discuss the ion at 
m/z 154. This ion is also observed for other long chain unsaturated carboxylates, 
e.g. oleic and linoleic acid. A direct bond cleavage would produce [CO2]CaCl2−•. 
Chapter 5
114
In the CID spectrum of C20H31COOCa35Cl37Cl− the above m/z 154 peak is cleanly shifted to m/z 156 and so the product ion contains two Cl atoms. The exact mass 
measured for m/z 154 by FTMS (153.8907) is within experimental uncertainty 
equal to the calculated value for [CO2]CaCl2−• (153.8906) and so the elemental composition is [C, O2, Cl2, Ca]. In an MS3 experiment this species was found to dissociate by loss of CO2 and so we conclude it indeed to be [CO2]CaCl2−•. Our calculations indicate that this species is stable by 105 kJmol-1 with respect to CO2 loss and that electron detachment to produce CO2 + CaCl2 requires a further 95 kJmol-1. Inspection of the calculated optimized geometries of [CO2]CaCl2−• and its Mg counterpart, see Figure 4, indicates that these intriguing species can be 
viewed as CO2 captured by the anionic salts CaCl2−• and MgCl2−•. However, a population analysis suggests that the unpaired electron (and charge) may well 
reside on the CO2 moiety.
Figure 4. CBS-QB3 optimized structures for [CO2]MgCl2−• and  [CO2]CaCl2−•
They are currently the subject of a further study. The related species [CO2]MgX− 
(X = OH, Cl, Br) have recently been studied by Dossmann et al.(21)
Retinoic Acid (atRA)
Metabolism activates vitamin A (retinol) into all-trans retinoic acid (atRA) (22). 
Abnormal levels for atRA may cause and/or permit epithelial degeneration, 
such as xerophthalmia, and neurological disorders, such as schizophrenia, 
Parkinson’s disease, Huntington’s disease and Alzheimer’s disease (23). 
Endogeneous atRA levels are assessed by LC-MS/MS operated in the positive 
ion mode; the negative ion mode is reported to be less sensitive than the positive 
mode (18). In the negative mode, the retinoic acid carboxylate anion dissociates 
only by loss of the non-structure characteristic fragment CO2, see Figure 5a.
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Figure 5. ESI-CID ion trap mass spectra of (a) the retinoic acid carboxylate 
anion; (b) the anioncomplexed with CaCl2 and (c) the labeled retinoic acid 
complex ion.
When deprotonated atRA is complexed with CaCl2, loss of CO2 still occurs - and also the hydrolysis reaction is seen to produce HOCaCl2−, m/z 127, see Figure 5 - but now an additional intense fragment ion is observed at m/z 303, 
corresponding to the loss of 106 Da. For the D-labelled analogue retinoic acid-d5 
this peak shifts to m/z 308 (loss of 106 Da). This leads us to propose that loss of 
106 Da corresponds to the loss of C8H10 and a possible extrusion mechanism is given in Figure 6.
Although we do not have definitive evidence, it is tempting to view this 
dissociation as occurring via a [CO2]CaCl2−• shift, a species observed as an 
isolated entity in the previous section. Apart from these intriguing mechanistic 
aspects, attachment of CaCl2 to the retinoic carboxylate anion leads to a highly 
structure characteristic dissociation product that may greatly aid its qualitative 
and quantitative analysis.   
The observation that the precursor ion can also eliminate CO2 shows that 
calcium can form an organometallate via decarboxylation(14).
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Figure 6. Proposed mechanism for elimination of 106 Da from the retinoic 
carboxylate anion complexed with CaCl2.
Carboxylate substituted superhalogens RCOOMX2−, notably RCOOCaCl2−, can be generated by Electrospay ionization of mixtures of the acids RCOOH 
acid and salts MX2 and their collision induced dissociations (CID) can readily be obtained. For the earth alkali metals an important product ion observed in 
the ion trap is HOMX2−; this ion is also present when the system contains no hydrogen atoms, as in C6F5COOCaCl2−.  In addition, the labeled ions DCO2CaCl2− and CD3CO2CaCl2− both form HOCaCl2− to the exclusion of DOCaCl2−and so we conclude that formation of HOCaCl2− occurs via hydrolysis by residual water present in the ion trap via:
RCOOCaCl2−   +   H2O               RCOOH   +   HOCaCl2−
If no water is present (as for the triple quadrupole collision cell) formation 
of HOCaCl2− can still occur, but only if the size of R permits the more energy demanding unimolecular process, a 1,4-H shift that leads to expulsion of an 
olefin and  a CO molecule. A McLafferty type rearrangement followed by loss 
of an olefin and a CO2 molecule accounts for the co-generation of HCaCl2− ions.When complexed with MX2 (M = Mg, Ca, Sr, Ba, X = Cl, Br), the CID mass spectra of long chain unsaturated aliphatic carboxylate anions display backbone 
Conclussions
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cleavages involving the loss of specific olefin molecules which readily reveal the 
position of the double bond(s). Such long chain ions also produce the species 
[CO2]MX2−• which were characterized by CID experiments and which can be viewed as a CO2 molecule captured by the anionic salt MX2−• species.  
Deprotonated retinoic acid complexed with CaCl2 shows an abundant loss of CO2 showing that CaCl2 can produce organometallates by decarboxylation. In addition, another intriguing dissociation is observed, viz. loss of 106 Da which is 
proposed to correspond to loss of meta-xylene, a highly structure characteristic 
dissociation.
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Prostate cancer (PCa) is a common malignancy in men and its incidence 
continues to rise in many countries. Although the introduction of the PSA test 
has improved  the management of the disease considerably, its low specificity has 
led to overtreatment of many prostate cancers, including aggressive treatments 
in older men considered to be at low risk for progression of the disease. Despite 
known limitations of the PSA test, it is worldwide used as a cancer marker for 
diagnosis, as well as for monitoring of success of radical prostatectomy and 
biochemical recurrence. 
Searching for novel and/or complementary markers to PSA for the diagnosis 
and prognosis of PCa is still a relevant topic in PCa research. During the last 
decade, it has been addressed by using the most advanced technologies at 
different levels i.e. genes (genomics), transcripts (transcriptomics), proteins 
(proteomics) and metabolites (metabolomics).  
In this thesis, we aimed to identify and validate novel metabolites or proteins in 
tissue or bio-fluids, which might improve the diagnosis and/or the prognosis of 
PCa. We used analytical approaches, and particularly mass spectrometry to study 
the role of some metabolites and proteins, particularly along the arachidonic 
acid (AA) pathway, in the diagnosis and prognosis of PCa. 
Figure 1, describes the main pathways outlined in this thesis, after combining the 
results from a targeted metabolomics in serum and also a shotgun proteomics 
approach in PCa tissue. Most of the proteins studied in this thesis belong to 
the eicosanoid signalling pathway, from phospholipases cleaving AA from cell 
membranes, to specific hydroxylases such as LX15B, which converts AA to the 
bioactive molecule 15-HETE.
Primarily, we were interested in developing analytical methods by using liquid 
chromatography and mass spectrometry to identify statistically significant 
metabolites in serum samples from PCa patients and controls. In this process, 
we evaluated the concentrations of tryptophan and kynurenine (indicators of 
the IDO enzyme activity), as well as six metabolites within the arachidonic acid 
(AA) pathway (5-HETE, 8-HETE, 11-HETE, 15 HETE and AA), for the diagnosis 
and the prognosis of PCa.
General Discussion
General Discussion
123
High	levels	in	serum
Marker	for	prognosis
Up-regulated	in	PCa tissue
Marker	for	prognosis
AA
15-HETE
Tryptophan
Kynurenine
Up-regulated	in	PCa tissue
Not	a	marker	for	prognosis
Up-regulated
in	PCa tissue
Up-regulated
in	PCa tissue
Down-regulated	in	PCa tissueDown-regulated	in	PCa tissueMarker	for	Prognosis
Down-regulated	
in	PCa tissue
Down-regulated
in	PCa tissue
Up-regulated	
in	PCa tissue
Up-regulated	in	
Metastatic	PCa (39)
No	changes	in	serum
No	changes	in	serum
Reduced	in	Advanced	PCa
Marker	for	Prognosis
Figure 1. Overview figure illustrating the main metabolites, proteins and 
pathways discussed in this thesis. A STRING tool (www.string-db.org) was 
used to show the interaction of proteins along the AA pathway. Two proteins: 
AGR2 and IDO2, do not belong to this pathway, but they were also discussed 
in this thesis.
IDO enzyme activity is not a marker for detecting PCa
Considering the list of potential metabolic markers associated to PCa progres-
sion reported by Sreekumar et al. in 2009 (1), we decided to explore analyti-
cal tools to identify novel markers in serum samples from patients diagnosed 
with PCa. The first approach was the study of an enzyme activity, expressed as 
the kynurenine/tryptophan (Kyn/Trp) ratio, for indoleamine 2, 3-dioxygenase 
(IDO2, Figure 1). This enzyme is produced within tumours and initiates the con-
version of tryptophan (Trp) within the kynurenine (Kyn) pathway, resulting in 
the production of immune-suppressive catabolites known to inhibit T- cell stim-
ulation and to cause T-cell apoptosis (2). In addition, it was demonstrated by 
Feder-Mengus et al. (3) that IDO2 gene expression is significantly higher in PCa 
tissue compared to benign prostate hyperplasia (BPH) tissue. Thus, the study 
of metabolites produced along the kynurenine pathway was of interest in our 
search for non-invasive markers.
We used a HPLC method with fluorescence detection for the quantitation of 
tryptophan and kynurenine in serum. We did not find any statistically significant 
difference between the Controls/ERSPC and the group of PCa patients (Chapter 
2, Figure 1). Therefore, we concluded that neither serum concentrations of these 
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metabolites, nor the ratio Kyn/Trp, an indicator on the IDO enzyme activity, can 
be considered as novel markers for the diagnosis of PCa. 
We used a standard addition method, using at least five external calibrators 
to accurately calculate the concentrations of these metabolites, and in all cases 
the R2 values were higher than 0.99. We used 1-methyl tryptophan as an inter-
nal standard, and we have used both UV and fluorescence detectors because 
these methods and instrumentation can be used routinely, and can also be inde-
pendently validated for clinical purposes.
One of the major challenges in metabolomics is the clinical applicability of po-
tential metabolites in the diagnosis or prognosis of the disease. Several studies 
have demonstrated the potential applicability of metabolomics for PCa diagno-
sis (Chapter 1, Table 2), but unfortunately none of them is used in the clinic so 
far. The analytical methodology employed to detect/quantify metabolites still 
remains an important drawback in metabolomics and most of the methods and 
studies lack validation between different laboratories.
Different studies using metabolomics approaches have reported an increment 
in the concentration of Kyn in PCa tissue (1, 4). However, we found that this 
alteration in tissue does not lead to changes in serum. Although metabolic al-
terations in the tryptophan pathway might be occurring in the prostate, tryp-
tophan catabolism occurs in many cells of the body, thus affecting the concen-
tration of its metabolites in the bloodstream. Metabolites in biofluids are highly 
affected by diet, physical activity, environment or drug intake. Recent advances 
in the chemistry of chromatography columns, as well in the commercial use of 
heavy labelled standard isotopes, might contribute to the improvement in the 
quantitation of these molecules using mass spectrometry. HILIC chromatogra-
phy columns have been employed recently for both the untargeted and targeted 
analysis of polar compounds in biofluids (5, 6). Extended cohorts of individuals, 
analysing even thousands of samples, might contribute to compensate the var-
iation in biological samples, and they are required to truly evaluate the role of 
particular metabolites in the diagnosis of PCa.
Arachidonic acid pathway and its role in PCa progression
The Arachidonic Acid (AA) pathway is a well-studied biological pathway 
that triggers the cell membrane by the action of phospholipase A2-type 
(PLA2) enzymes (7). The metabolism of AA includes cyclooxygenase (COX), 
lipoxygenase (LOX) and P450 epoxygenases that generate eicosanoids, 
including prostaglandins (PGs), leukotriens (LTs), thromboxans (TXs), 
hydroxyeicosatetraenoic acids (HETEs), epoxyeicosatetraenoic acids (EETs), and 
hydroxyperoxy-eicosatetraenoic acids (HPETEs) (8, 9).
Our main interest when searching for novel and non-invasive markers for PCa 
focussed on the use of analytical approaches using liquid chromatography and 
mass spectrometry. Metabolites produced by lipoxygenase enzymes along the 
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AA pathway had been proposed as a target for preventing and treating PCa 
by Yang et al. (10). In addition, Schumacher et al.(11), observed a decrease in 
the concentration of AA in PCa tumours. Therefore, we decided to develop 
an analytical method for the simultaneous quantitation of HETEs and AA in 
serum by using ultra-high performance liquid chromatography tandem mass 
spectrometry (UHPLC-MS/MS).
In Chapter 3, we described a targeted metabolomics study of AA and some 
of its metabolites in serum samples from patients with PCa as well as other 
malignancies. In a discovery phase, we have found that the concentration of 
hydroxyeicosatetraenoic acids (HETEs) was higher in six out of twenty PCa 
patients, when compared with patients having low PSA levels.  We validated 
these findings in an extended cohort with more than two hundred patients 
exhibiting different stages of PCa. We found that six out of nineteen samples in 
the most advance stage group (Group 5) exhibited high concentrations of the 
same metabolites, as well as a reduction in the serum concentration of AA.
We performed a partial validation of our analytical methodology, and we 
found R2 values of 0.99 after constructing calibration curves using commercial 
standards (AA, 5-HETE, 15-HETE, 12-HETE and AA d8 amd 15-HETE d8) 
and also when the eicosanoids where spiked into artificial serum. In addition, 
we analysed the reproducibility of both peak area and retention time over a 
period of 48 h at 4 ºC, which was the maximum time the samples stayed in the 
autosampler before MS injection. We also used heavy isotopic labelled standards 
(AA-d8 and 15-HETE-d8) to ensure an accurate quantitation of metabolites. A 
serum sample from a healthy individual was used as a Quality Control (QC) 
sample. Each sixth sample was analysed as an QC to confirm the analytical 
reproducibility of the measurements. 
Several methods (12-16) have been reported for the quantitation of eicosanoids 
in plasma or serum using mass spectrometry. Some of these methods proposed 
the use of solid phase extraction cartridges to both clean up and concentrate 
eicosanoids before MS acquisition. We decided to use a simultaneous protein 
crash-dilution method using cold methanol, because it allows an efficient 
recovery of metabolites, and the high throughput required when hundreds of 
samples are analysed.
We focused on the molecules produced mainly by lipoxygenases-like enzymes 
and found that concentration of HETE metabolites correlate with the stage 
of PCa. However, several and different eicosanoids might also be altered 
as a consequence of PCa progression and they could be potentially analysed 
using a similar approach. Further experiments are needed to analyse the role 
of leukotriens (LTs) and thromboxans (TXs) in the diagnosis and the prognosis 
of PCa. In addition, similar analytical methodologies could be used to study 
the role of these molecules after in vitro targeting of PCa cells with particular 
anticancer drugs.
It is known that eicosanoids like HETEs and leukotriens are bioactive fatty acids 
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AA pathway in PCa tissue
The search for novel and non-invasive markers for PCa diagnosis and prognosis 
resulted in a new set of small molecules associated to PCa progression: HETEs. 
However, several metabolic reactions in the human body, including the processes 
involved in inflammation, can be responsible for the elevated concentration 
of these molecules in serum. To further evaluate the role of the AA pathway 
(the pathway where the HETEs are produced), we set out to identify possible 
proteome signatures of the enzymes producing these metabolites in PCa tissue. 
In Chapter 4, we aimed to understand whether the deregulated concentration 
of AA and its metabolites in serum, could be associated with a de-regulation 
of particular proteins in prostate tumours. In addition, using a proteomics 
approach, and particularly, a label free quantitation (LFQ) strategy, we aimed to 
identify novel molecular pathways associated to the PCa progression. 
We used Orbitrap technology to identify statistically significant proteins in PCa 
tissue compared to normal adjacent tissue (NAP) and independently validated 
the expression of three proteins using tissue microarray with 481 patients. We 
found that normalised abundances for the proteins: AGR2, and FASN and TEBP, 
were higher in PCa tissue than in NAP in our proteomics dataset. In addition, we 
found that normalised abundances of LX15B, LKHA4 and HYES were lower in 
PCa, and could have a potential clinical applicability for PCa diagnosis. Further 
validation experiments using tissue immunohistochemistry are still required to 
confirm the role of these proteins in PCa prognosis.
When analysing the proteins of the AA pathway by tissue immunohistochemistry, 
we found that expression of LOX5 was higher in PCa, but LX15B expression 
was almost comparable between PCa and NAP. Although we could not detect 
the LOX5 protein directly in our proteomics analysis, we evaluated the tissue 
microarray (TMA) expression data for LOX5. We found that expression of the 
protein could be an indicator of biochemical recurrence (BCR) after radical 
prostatectomy, thus indicating a prognostic role for PCa. 
Arachidonic Acid and its MS fragmentation pattern
Fatty acids like arachidonic acid (AA) ionise well at low pH to produce 
mass spectra in the negative mode. Several methods have been reported to 
quantify AA in different matrices using HPLC tandem mass spectrometry 
(17), and in most cases a unique fragmentation of m/z: 259.2410 is reported, 
corresponding to the carboxylate loss in the carbon chain. In Chapter 5, 
involved in the regulation of a diverse set of homeostatic and inflammatory 
processes (17-19). Therefore, the question whether HETE metabolites are PCa 
specific, or whether they are side products of tumour progression involving 
inflammation processes, remains to be answered.
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we report a novel approach to study the fragmentation pattern of fatty acids 
to identify double bonds in the carbon skeleton. We selected AA because of its 
biological importance in the development of cancer, and particularly PCa. The 
process called remote charged fragmentation, has been successfully used using 
Ca2+ and Mg2+ cations for the structural characterization of peptides using mass 
spectrometry, and we have shown that the same cations can be used to analyse 
fatty acids and lipids with mass spectrometers.
Particularly, lipids are complex molecules characterised by having different 
numbers of carbon chains, and also different numbers of double bonds distribut-
ed along the carbon chains. These characteristics make the structural characteri-
sation of lipids a real challenge, especially when there are no differences in mass 
between two or more isomers. Recently, the use of additives like Li+ and Cs+ 
salts have improved both the detection and the identification of lipid species in 
different biological matrices (20). Therefore, the proposed methodology using 
double charged cations in fatty acids can be extrapolated to the study of lipids 
with biological relevance to PCa. Further experiments are needed to understand 
the role of remote charge fragmentation in lipid species in several matrices such 
as plasma, and tissue cell lines.
AA pathway and PCa progression: A transversal readout
In this thesis, a new set of molecules possibly involved in PCa progression has 
been described. Despite the lack of direct clinical applicability of the HETEs as 
markers for PCa diagnosis, HETEs show a potential to predict PCa relapse after 
radical prostatectomy and these molecules might claim the role of AA pathway 
as a therapeutic target for the management of prostate carcinoma. We have 
shown that both metabolomics and proteomics results highlighted differentially 
expressed molecules associated to PCa (i.e. eicosanoids and proteins involved in 
arachidonic acid pathway and fatty acid metabolism). 
In order to understand the cause of high concentration of HETEs in PCa 
patients, the biological relevance of the AA pathway, and the correlation of our 
proteomics data with available mRNA expression data, we analysed publicly 
available data sets for gene expression from PCa tissue and benign prostate 
tissue using Oncomine (21). Yang et al (10). previously reported that the mRNA 
level of COXs and LOXs, and the intracellular levels of the metabolite 12-HETE, 
are altered among androgen dependent and independent cell lines and their 
corresponding xenograft models. Thus, in first instance, we checked whether 
the high concentration of the metabolites HETEs could be caused by any 
over-expression of the genes belonging to the AA pathway. Six data sets were 
analysed and checked for RNA expression of lipoxygenases, cyclooxygenases, 
epoxygenases as well as other enzymes involved in the AA pathway and lipid 
metabolism.
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Analysis of mRNA expression is presented in Supplementary Table 1. In this 
table, a down regulation of lipoxygenases ALOX5, ALOX12, ALOX15B is 
observed in PCa compared to benign prostate. For ALOX5, these results were 
contradictory to previous reports in literature where lipoxygenase-5 was 
reported as over-expressed in PCa (9, 22). In our proteomics dataset, we found 
an down-regulation in LX15B, which is in agreement with findings reported 
by Shapell et al., who proposed it as the most characteristic alteration (down-
regulation of LX15B) of AA metabolism in PCa (23). In Oncomine, ALOX15 
was found to be over-expressed in only one study (Arredouani (24)), but the 
combined analysis showed no statistical significance (p > 0.05). These results 
suggested that elevated serum concentrations of 5-HETE and 15-HETE in our 
PCa patients could not be explained by an up-regulation of mRNA expression of 
the enzymes converting AA into the above-mentioned metabolites.
By the metabolomics approach (Chapter 3), we also found an elevated 
concentration of the metabolite 11-HETE, a product of the AA metabolism 
produced by COX-1 and COX-2 (cyclooxygenases, GN: PTGS1 and PTGS2). 
It has been suggested that cyclooxygenases are associated to PCa progression. 
Shapell et al. found in human samples from RP specimens that expression of 
COX-2 was elevated only in high-grade tumours (23). In addition, Khor et al., 
studied the association of COX-2 expression with outcome in patients with PCa 
who had radiotherapy, indicating that COX-2 expression was highly associated 
with biochemical recurrence (25). Amirian et al. conducted a pathway-based 
analysis to investigate the role of putative functional AA metabolism gene 
polymorphisms in prostate cancer susceptibility (26). From the single-locus 
analyses, they have found that one SNP from each of the two major branches of 
AA metabolism, the prostaglandin synthesis sub pathway (PTGES2 rs10987883) 
and the leukotriene synthesis sub pathway (LTA4H rs1978331), may be relevant 
to prostate cancer risk (26).
Our analysis using Oncomine presented in Supplementary Table 1 shows that 
both COX-1 and COX-2 mRNA expression are down-regulated in PCa (combined 
analysis p < 0.05). Considering the controversial COX-2 expression in human 
PCa cells reviewed by Patel et al.(9), as well as the down-regulation of COX-2 
described in Table 2, we conclude that high concentrations of the metabolite 11-
HETE cannot be directly explained by an association with the level of mRNA 
expression of COXs enzymes. 
In our targeted metabolomics study (Chapter 3), we found that eicosanoids 
concentration exhibited an outlier-like profile, so we decided to look into more 
detail whether the enzyme mRNA profile contains also possible outliers, for all 
the lipoxygenases the average values were similar between cancer and normal 
tissue, with the subsequent absence of statistical significance.
Interestingly, Oncomine expression data also describes an up-regulation in 
PTGES3 (TEBP protein), in agreement with our protemics results presented in 
Chapter 3. To the best of our knowledge, this protein has not been reported 
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Phospholipases: key enzymes for PCa
In this thesis, we have shown a reduced concentration of AA in serum from PCa 
patients in the most advanced stage of the disease. In addition, our proteomics 
study in PCa tissue indicated that cPLA2 is differentially abundant compared 
to benign prostate tissue The Oncomine results presented in Table 1 show 
that PA2GA (GN: PLA2G2A, p = 1.24E-5, in combined analysis), PA24A (GN: 
PLA2GIV, p = 0.018), PAFAH (GN: PLA2G7, p = 3.91E-7, in combined analysis) 
and PA2GX (GN: PLA2G10, p = 0.014) are overexpressed in PCa, thus confirming 
the potential role of this family of enzymes in PCa progression.
As mentioned before, it is well known that AA is mobilized from cellular 
membrane glycerolipid pools by the action of phospholipase A2 enzymes, 
PLA2, leading to the production of free fatty acids and lysophospholipids. The 
PLA2 enzymes consist of a family with 20 members identified in mammals. This 
family can be classified into 4 classes based on their nucleotide and amino acid 
sequence, namely sPLA2, cPLA2, calcium independent cytosolic and PAF acetyl-
hydrolase enzymes (7, 27). Association of different enzymes of the PLA2 family 
with PCa has been described in literature (28-35). Mirtti et al. determined mRNA 
and protein expression of PLA2G2A during PCa progression in localized and 
metastatic prostate tumour. They found that both mRNA and protein expression 
were significantly higher in Gleason Grade 3+3 carcinoma compared to benign 
prostate tissues, but metastatic carcinoma expression decreased compared 
to primary carcinomas (33). Patel et al. studied the expression of cytosolic 
phospholipase A2 (PA24A) in PCa cells and they reported that the level of this 
enzyme was increased in androgen-insensitive PCa cell lines and suggested also 
that this enzyme played a role in cancer cell proliferation and apoptosis (32). 
PLA2G7 (PAFAH) is highly expressed in PCa (Chapter 4). This enzyme was for 
the first time identified by Vainio et al.  in a set of 9783 human tissue samples and 
it was proposed as a potential drug target specially in ERG positive PCa (36). 
Further validation studies performed by the same group indicated a correlation 
between staining intensity for PAFAH and Gleason Score in 50% of the cases, 
thus suggesting this enzyme as a biomarker for PCa. The same author reported 
the PLA2G7 inhibition by statins, a widely-used drug to lower cholesterol levels, 
as a therapeutic tool for the management of the disease (37). 
Considering the fact that high serum concentrations of HETEs, as well as 
a diminished serum concentration of AA in our PCa patients could not be 
explained by any alteration of mRNA or protein abundance of lipoxygenases 
and/or cyclooxygenases-type enzymes (PTGES1 and PTGES2); we suggest 
that the deregulation in concentration of AA metabolites might be associated 
to the deregulation of phospholipases. Thus, our proteomics results described 
before as marker for PCa diagnosis or prognosis, and it represents a new target 
for studying PCa progression.
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in Chapter 4, as well as the mRNA expression results presented in Table 1, fit 
the hypothesis that the phospholipases family can be seen as a relevant target to 
analyse PCa progression.
It is known that prostate tumours include a heterogeneous group of tumour 
growth patterns such as fused, ill-defined, cribriform and glomerular glandular 
structures, particularly in Gleason grade 4, and it has been shown that cribriform 
growth is a strong prognostic marker for distant metastasis and disease-specific 
death in patients with Gleason score 7 PCa (38). To date, possible correlations 
between arachidonic acid pathway and lipid metabolism and the above-
mentioned tumour growth patterns are missing, so further experiments in vivo 
(either using PCa-derived xenografts models or genetically modified mice such 
as PTENNULL as describe in reference (39)) should be performed to analyse 
the role of these enzymes in PCa progression. An effective way to identify the 
molecular mechanisms of enzymes in the AA pathway, or enzymes involved in 
lipid and fatty acid metabolism, is the selective inactivation/silencing of those 
genes by RNAi, by the use of advanced gene editing techniques such as CRISPR-
Cas9 (40), or by the use of chemical inhibitors (drugs). We have shown that our 
mass spectrometry methodologies are suitable for the analysis of eicosanoids, so 
they can be translated into in vivo experiments to further understand the role of 
these molecules in the development and progression of PCa.
In Chapter 4, we have shown that proteins associated to lipid metabolism were 
deregulated in PCa tissue. From our mRNA analysis with Oncomine, we have 
shown that FASN is overexpressed in PCa (p=2.87E-6 in combined analysis), thus 
confirming the link between fatty acid/lipid metabolism and PCa progression. 
FASN is probably the most extensively studied member of the lipogenic enzymes 
in the context of carcinogenesis. Overexpression of this enzyme has been reported 
in a variety of cancer including prostate, liver, ovarian, colon, endometrial and 
breast (41). Results from a number of studies suggest that FASN might serve as 
biomarker of PCa progression, with increased expression associated with a more 
aggressive phenotype (42). However, our results reported in Chapter 4, indicate 
that expression of FASN cannot be used as a predictor of biochemical recurrence, 
and therefore it is not a suitable prognostic marker for PCa. 
It has been shown that transgenic expression of FASN in cultured PCa cells 
increased the rate of proliferation and inhibited apoptosis(43). Down-regulation 
of FASN expression by siRNA, on the other hand, attenuated growth and induced 
apoptosis (44). In a separated study, FASN inhibition not only suppressed 
cell proliferation but prevented pseudopodia formation and suppressed cell 
adhesion, migration and invasion. FASN inhibition also suppressed genes 
involved in production of intracellular second messenger AA and androgen 
hormones, both promoting tumour progression (45, 46).
Lipid metabolism in PCa
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Ahmad et al., recently reported that the transcription factor PPARG as a promoter 
of metastatic PCa through the activation of lipid signalling pathways, including 
the overexpression of enzymes such as fatty acid synthase FASN (Chapter 4), 
and acetyl co-A carboxylase (ACC). It was also reported that high levels of 
PPARG correlate with FASN in PCa tissue and that high levels of PPARG/FASN 
and PI3K/pAKT pathway activation is an indicator poor prognosis(39). 
Fatty acid receptors termed peroxisome prolifelator-activated receptors (PPARs) 
belong to the nuclear hormone receptor superfamily of ligand inducible 
transcription factors. All three isotopes (PPARa, PPARb and PPARg) are known 
modulators of lipid metabolism. The important role of PPARs in carcinogenesis 
was highlighted by the ability of their ligand to affect cellular proliferation and 
differentiation or to interfere in apoptosis and angiogenesis. While different 
subtypes of PPARs may play a role in tumour progression in different cancer 
types, high level of expression of PPARG has been detected in PCa (47). 
It is known that PPARg is activated by endogenous ligands produced along the 
both the linoleic and arachidonic metabolism. Some of these ligands are the 
lipoxygenase products 13(S)-HODE and 15(S)-HETE (48). This could explain the 
fact that we only found high concentration of HETE metabolites in the group of 
patients at the most aggresive state of the disease.
Another enzyme associated to lipid metabolism identified in our proteomics 
in Chapter 4 is AMACR. It is believed that increased fatty acid oxidation is a 
predominant phenomenon in PCa because of its role as source of energy. Thus, the 
overexpression of the perixomal enzyme a-methylacyl-coA racemase (AMACR) 
required for oxidation of branch chain fatty acids, supports this hypothesis.
PCa cells exhibit increased expression of many lipogenic enzymes, often as a result 
of stimulation by oncogenic signalling pathways such as PI3K/Akt and HER2 
(46). Conversely, increased expression of fatty acid synthesis enzymes has been 
linked to activation of and nuclear localization of Akt/PKB in clinical tumour 
samples. Androgens, via the androgen receptor, activated the gene expression 
of lipogenic enzymes. Analysis of mRNA expression of lipogenic enzymes 
by Oncomine (Reviewed in (46)), revealed that mRNAs encoding lipogenic 
enzymes are increased in PCa, including those involved in de novo fatty acid 
synthesis (ATP citrate lyase (ACLY), acetyl-coA carboxylase-a (ACACA), fatty 
acid synthase (FASN), and long chain fatty acid acyl-coA synthetases (ACSL1, 
ACSL2, ACSL3, ACSL5). The transcription factor, sterol regulatory binding 
protein 1 (SREBP1) that regulates the expression of fatty acids and cholesterol 
signalling enzymes, was also increased in PCa.
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In this thesis, we have shown that the AA pathway plays a role in the development 
of PCa. It is known that AA interacts with different genes and pathways already 
described to be involved in PCa development. Genomic loss of the PTEN locus, 
leading to a constitutively active PI3K/Akt pathway, occurs in 30-70% of prostate 
tumours. In addition, 8q amplification including the Myc gene, is present in 30% 
of tumours, thus representing the most common genetic alterations known in 
PCa (49). 
Mutations in PTEN have been found in approximately 15% of primary PCa, 
rising to 50% of expression loss in advanced primary PCa (50), and more than 
60% of patients with PCa metastasis have also been associated with alterations in 
PTEN (50, 51). Oxidation of PTEN by AA metabolism decreased PTEN activity, 
resulting in elevated PIP3 levels and increased signalling through Akt and its 
downstream targets (52). The AA pathway contributes to PCa progression by 
modulating PCa cell proliferation, apoptosis, angiogenesis and metastasis. 
Growing evidence suggests that the AA pathway can stimulate PI3K/Akt in PCa 
cells. Incubation of PCa cancer cell lines with AA causes increased prostaglandin 
E2 synthesis, followed by induction of PI3K-mediated Akt activation, which 
then leads to increased cell proliferation (53).
Inhibition of the cyclooxygenase-2 (COX-2, described above as an enzyme 
involved in eicosanoids production) has been shown to induce apoptosis in 
both androgen-responsive LNCaP and androgen-unresponsive PC-3 cells, by 
blocking Akt phosphorylation and by down-regulation of cyclin D1(54). As 
PTEN is non-functional in the LNCaP (mutation/deletion) and PC-3 (deletion) 
PCa cell lines, these results suggest that AA/eicosanoids could stimulate PI3K/
Akt in the absence of PTEN. Several studies examining regulation of PI3K/Akt 
by AA or eicosanoids were conducted with pharmacological inhibition of AA 
or eicosanoid production, showing that AA and eicosanoids have a stimulatory 
effect on PI3K/Akt signalling (49).
Arachidonic acid is one major ingredient of animal fats and the biologically 
active lipids from this substrate have crucial roles in chronic inflammation 
and cancer (19). Epidemiological, clinical and animal studies provide evidence 
that activation of the COX and LOX pathways during inflammation and 
carcinogenesis results in aberrant metabolism of arachidonic acid, which may be 
one mechanism involved in the contribution of dietary fats to carcinogenesis (19). 
The COX pathway has been suggested to be involved in PCa development and 
progression (9). Particularly, COX-2 has been correlated with areas of increased 
chronic inflammation (high number of T-lymphocytes and macrophages) and 
increased micro-vessel density. In addition, it has been proposed that cytokines 
from the local inflammatory infiltrate induces COX-2 expression in stromal 
Arachidonic acid and genetic alterations in PCa
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tissues and angiogenesis, and may form a link between chronic inflammation 
and cancer development (9).
Chronic inflammation is known to be involved in the development of cancer. 
In PCa, inflammation could be caused by several environmental factors, such 
as infections, dietary factors, hormonal changes and other environmental 
exposures that yet remain unknown (55). Diet has been brought forward as one 
of the environmental factors involved in inflammation and PCa development, 
although studies also showed contradictory results. High polyunsaturated 
fat consumption was found to increase the risk of high-grade (Gleason score 
8-10) PCa, as shown in reports from the Prostate Cancer Prevention Trial(56). 
Linoleic acid (LA) is the major component of polyunsaturated fat diets in the 
Western countries, which turns into AA, the substrate for production of pro-
inflammatory prostaglandins E2 and leukotriene B4. Therefore, increased 
intakes of polyunsaturated fats could be involved in PCa through their role in 
inflammation (57). 
It has been proposed that pro-inflammatory mediators within the prostate 
can lead to a state of chronic inflammation, resulting in lesions of proliferative 
inflammatory atrophy that may lead to prostatic intraepithelial neoplasia (PIN) 
and eventually prostatic carcinoma (57, 58). Dietary fat as a possible source of 
inflammation is the most frequent risk factor for PCa. Although epidemiologic 
data on total fat consumption as well as ingested fat quality remains inconclusive, 
experimental data strongly suggest that essential fatty acids such as omega-6 
and omega-3 polyunsaturated fatty acids that must be ingested in the diet play 
an important role in prostate carcinogenesis (57, 58).
The publications that link total fat consumption to PCa risk or progression 
remains controversial (59). Although animal studies repeatedly show that 
reducing dietary fat intake slows tumour growth, multiple case-control studies 
and cohort studies have not found any association between total fat consumption 
and PCa risk (59). High consumption of saturated fats such as those found in 
butter, lard, and animal meats do not seem to be associated with overall PCa 
risk, but they may be associated with a slight increase in biochemical recurrence 
after treatment. It is hypothesized that saturated fats may lead to increased 
circulating IGF-1, which in turn leads to PCa progression, although this remains 
speculative (59, 60).
Emerging data suggest that omega-3 fatty acids, which are found primarily in 
cold water oily fish like tuna, salmon, herring, and swordfish, as well as flaxseed, 
may slow the growth of many tumours, including prostate (61). In vitro and 
animal studies suggest that these fats induce anti-inflammatory, pro-apoptotic, 
anti-proliferative, and anti-angiogenic pathways making them a perfect anti-
tumour molecule. A phase II prospective randomized trial of a low-fat diet with 
fish oil supplementation in men undergoing radical prostatectomy showed 
omega-3 supplementation 4–6 week prior to RP decreased PCa proliferation (56), 
but further experiments in vitro and in vivo have to be performed to understand 
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molecular mechanisms of omega-3 fatty acids and tumour progression.
Chronic inflammation that is associated with different types of cancers, is 
typically associated with increased NF-kB activity and it is casually linked to 
tumour progression. It is known that PPARg agonist the production of pro-
inflammatory signalling proteins such as TNF, IL-6 and MCP-1 could be inhibited 
by PPARG agonist. PPARG is expressed in tumour cells and infiltrating immune 
cells, and there is evidence that anti-inflammatory activities are mediated by 
PPARG in many cell types (62). 
Brasky et al. reported that, within the Selenium and Vitamin E Cancer 
Prevention Trial, plasma phospholipid levels of long-chain omega-3 fatty acids 
(including eicosatetraenoic acid (EPA), docosapentaenoic acid (DPA), and 
docosapentaenoic acid (DHA)) measured in blood samples collected at baseline 
are positively associated with subsequent risk of low-grade, high-grade and total 
PCa (63). These observations have been considered incompatible with previous 
hypotheses suggesting that omega-6 fatty acid promotes tumour development; 
the latter because AA metabolites have pro-inflammatory and pro-angiogenic 
effects. On the other hand, it is believed that omega-3 fatty acids are thought to 
protect from cancer because they are substrates for the same metabolic enzymes 
used by omega-6 derived eicosanoids (64). Further work using animal models 
should be performed to analyse the role of a diet rich in omega-3 fatty acids on 
PCa tumour development. Particularly, the use of PCa xenografts models, where 
the tumour can be genetically and biochemically characterised, could be used to 
understand molecular mechanisms behind the fatty acid metabolism and PCa 
progression. 
Concluding remarks
In this thesis, we first wondered whether small molecules in serum could 
distinguish between healthy individuals and PCa patients. Although we 
only analysed two pathways of the metabolome, we could conclude that the 
concentrations of tryptophan and kynurenine, both belonging to the tryptophan 
pathway, cannot be used as diagnostic markers of PCa. On the other hand, 
and taking advantage of the state of the art analytical techniques such as 
liquid chromatography and mass spectrometry, we have shown that serum 
concentrations of hydroxyeicosatetraenoic acids (HETEs), a class of eicosanoids 
produced along the AA pathway, are associated with the stage of the disease. 
We also questioned whether the proteins producing the HETEs eicosanoids, 
could play a role in the diagnosis and prognosis of PCa, and we performed 
a proteomics screening in PCa tissue. We found that some enzymes involved 
in fatty acid and lipid metabolism (FASN, LOX5, LX15B, TEBP, LKHA4 and 
HYES), are deregulated in PCa tissue, and also that immunostaing of LOX5, 
and enzyme of the AA pathway, can predict biochemical recurrence of PCa after 
radical prostatectomy.
General Discussion
135
We believe that the experimental approaches used in this thesis can be 
incorporated directly in the study of PCa, by complementing the information 
obtained by gene sequencing, RNA expression, epigenetic profiling, and all the 
other techniques used nowadays to understand the origin and the development 
of prostate cancer. Our contribution to the field is the discovery of novel molecules 
within the AA pathway, that could be both markers for diagnosis and prognosis, 
as well as therapeutic targets for the disease. Further research is required to 
understand the molecular mechanisms associated with the arachidonic acid, 
the eicosanoids, and the enzymes involved in the transformation of these 
metabolites. 
Although the results described in this thesis do not have any potential application 
in the clinic so far, we believe that both the eicosanoids and the proteins in the 
AA pathway will have an impact on future research in the field. Recent technical 
improvements in mass spectrometry and liquid chromatography, will be of 
interest for the analysis of eicosanoids from serum or plasma from PCa patients 
at particular moments of the treatments (diagnosis, before surgery, after surgery, 
or response to treatment). In addition, targeted proteomics profiling of AA 
proteins in PCa biopsies should open ways for choosing an optimal treatment 
for PCa and/or to evaluate the response towards a cancer therapy.
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Supplementary Table 1. mRNA expression of Arachidonic acid pathway 
enzymes in normal and prostate cancer.
Gene Study
Fold 
change p-value
Meta-
analysis PCa NAP
PCa/
NAP p-value (N) (N)
ALOX5 LaTulippe (65) -1.535 0.013 23 3
Tomlins (66) -2.241 4.23E-5 0.007 29 22
ALOX12 Luo (67) -8.838 0.004 NA 15 15
ALOX15 Singh (68) -1.769 0.016 52 50
Arredouani (24) 1.582 2.93E-4 0.508 13 8
ALOX15B Arredouani (24) -2.905 4.40E-2 13 8
Lapointe (69) -1.544 1.22E-4 0.022 60 40
COX-1 Varambally (70) -10.513 4.27E-4 7 6
Grasso (71) -2.803 3.44E-4 59 28
Singh (68) -1.672 7.00E-3 0.007 52 50
COX-2 Vanaja (72) -2.826 1.50E-2 27 8
Arredouani (24) -2.497 5.00E-3 13 8
Wallace (73) -1.694 6.00E-3 69 20
Tomlins (66) -1.724 4.70E-2 0.031 30 22
PTGES3 Lapointe (31) 1.093 0.012 62 40
TCGA 1.011 0.016 61 45
Singh (30) 2.419 7.56E-4 50 50
Tomlins (28) 1.902 0.005 30 23
Vanaja (34) 1.415 0.012 27 8
Luo (29) 1.202 0.05 0.027 15 15
LTAH4 LaTulippe (65) -1.298 4.71E-5 23 3
Holzbeierlein -1.257 0.008 35 3
Wallace (73) -1.151 0.028 0.018 69 20
EPHX2 TGCA -1.16 5.12E-6 61 45
Tomlins (66) -1.98 0.005 30 23
Arredouani (24) -1.707 0.016 13 8
Grasso (71) -1.225 0.036 0.005 59 28
PLA2G2A Singh (68) 4.608 4.23E-6 52 50
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Lapointe (69) 2.922 2.05E-5 62 40
Tomlins (66) 4.333 6.00E-3 30 23
Holzbeierlein (74) 2.332 3.00E-3 1.24E-5 35 3
PLA2G4 Welsh (75) -1.675 4.41E-4 25 9
Varambally (70) -1.641 5.00E-2 7 6
Arredouani (24) -1.56 1.80E-2 0.018 13 8
PLA2G7 Singh (68) 5.155 3.70E-14 52 50
Welsh(75) 4.463 7.17E-7 25 9
Vanaja (72) 2.889 1.16E-7 27 8
Grasso (71) 2.628 2.21E-6 59 28
Lapointe (69) 2.238 6.46E-8 41 60
Taylor (76) 1.917 5.34E-6 131 29
Liu (77) 1.663 5.31E-5 44 13
Yu (78) 1.592 9.21E-7 65 23
Arredouani (24) 2.346 5.00E-3 13 8
Luo (67) 2.193 1.70E-2 15 15
Varambally (70) 2.003 5.00E-3 7 6
Holzbeierlein (74) 1.696 2.63E-4 3.91E-7 31 2
PLA2G10 Varambally (70) -1.906 1.40E-2 NA 7 6
PTEN Arredouani (24) 1.515 5.20E-5 NA 13 8
Lapointe (69) -1.722 1.57E-10 62 40
Singh(68) -1.638 3.18E-4 52 50
Magee(79) -1.52 8.00E-3 3.18E-4 8 4
FASN Singh (68) 5.644 1.96E-6 52 50
Welsh (75) 3.211 4.90E-8 25 9
Vanaja (72) 3.198 7.65E-5 27 8
Yu (78) 2.141 4.19E-6 65 23
Taylor (76) 1.564 2.87E-6 131 29
Luo (67) 4.662 4.80E-2 15 15
Wallace (73) 3.681 1.55E-4 69 20
Magee (79) 3.243 1.62E-4 8 4
Varambally (70) 1.852 7.00E-3 7 6
Liu (77) 1.852 3.00E-3 44 13
Grasso (71) 1.638 2.00E-3 2.87E-6 28 59
PPARG Varambaly (70) -15.837 1.20E-4 7 6
Grasso (71) -1.807 4.46E-4 28 59
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Taylor (76) -1.246 2.00E-3 131 29
Lapointe (69) -1.174 6.50E-2 1.00E-3 62 40
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Appendices
The Arachidonic Acid Pathway: A potential application in 
the diagnosis and prognosis of prostate cancer
Summary
Prostate cancer (PCa) is the most common cancer in men, and in 2012 more 
than 400,000 cases were diagnosed in Europe. Although the introduction of the 
PSA test improved the management of the disease, its low specificity has led to 
overdiagnosis and unnecessary treatments for men considered to be at low risk 
for progression of the disease. Thus, novel and reliable molecular markers are 
needed to improve the diagnosis of PCa and also to better differentiate indolent 
cases of PCa from those that will recur after initial treatment.
In this thesis, we aimed to identify and validate novel metabolites and proteins 
markers in tissue or bio-fluids, which could improve the diagnosis and/or the 
prognosis of PCa. We used analytical approaches to study the role of selected 
metabolites and proteins, particularly along the arachidonic acid (AA) pathway. 
We used targeted metabolomics approaches in serum to evaluate whether 
concentrations of molecules in two pathways could be used as markers for PCa. 
For tryptophan (Trp) and one of its metabolites, kynurenine (Kyn), we used an 
HPLC method with fluorescence detection on serum samples from older men 
having low PSA values and no PCa, as well as subjects diagnosed with PCa. 
We could not identify statistical differences between the groups and thus we 
concluded that neither the concentrations of these metabolites, nor the ratio 
Kyn/Trp, could be used as markers for PCa.
Next, we used a UHPLC-MS/MS method to evaluate the concentrations of AA 
and some of its metabolites in serum from PCa patients at different stages of 
the disease. We developed a method for the simultaneous quantification of six 
metabolites belonging to the AA pathway, and we used the results to evaluate 
PCa diagnosis. Interestingly, we found that a selected group of patients had 
higher concentrations of hydroxyeicosatetraenoic acid (HETE) metabolites, 
compared to the control group. We then used the same methodology on an 
extended and well defined group of patients having different stages of PCa, and 
we found that concentrations of HETE metabolites are associated with the most 
aggressive status of the disease. Concomitantly, we also found a reduction in the 
AA concentration in the same group of patients and these results (which may be 
related to each other) could be used as an indicator of PCa relapse after radical 
prostatectomy.     
In tissue, we used label free quantitative proteomics to identify proteins in PCa 
that are associated to diagnosis and prognosis and also to evaluate whether the 
altered concentrations of AA and  its metabolites in serum could be associated 
with a deregulation of particular proteins in the arachidonic acid (AA) pathway. 
We analysed the protein fraction from RNA isolation of 67 PCa tissue samples, 
consisting of 33 normal adjacent tissue (NAP) samples and 34 PCa samples, 
151
Summary
using nano-LC high resolution mass spectrometry. In addition, we validated 
the expression of four proteins by immunohistochemistry and we used tissue 
microarrays (TMA) to evaluate the prognostic performance of these markers. 
Remarkably, we found that FASN, AGR2, and one protein of the AA pathway: 
TEBP, were highly upregulated in PCa. In addition, TMA indicated that both 
low percentage of positive AGR2 tumour cells and low percentage of positive 
LOX5 tumour cells , are predictors of biochemical recurrence after radical 
prostatectomy. These results highlight the role of proteins in the AA pathway in 
the diagnosis and prognosis of PCa.
We have shown that proteins and metabolites in the AA pathway play a key role in 
PCa. To complement the structural characterisation of AA in mass spectrometry, 
we studied the fragmentation of AA in the presence of metal ions such as Ca2+ 
and Mg2+. We showed that the addition of these metal ions improved the 
fragmentation of AA in the gas-phase, and in particular such fragmentations 
provide the exact location of the double bonds in the carbon chain. Thus, this 
strategy could be further used to analyse extended sets of fatty acids and lipids 
using mass spectrometry, and also their role in diseases like cancer.
We conclude that we have shown that the experimental methodologies used 
in this thesis help to understand the role of the fatty acid metabolism and 
arachidonic acid pathway in PCa. Key metabolites such as HETEs and AA, as 
well as enzymes along this pathway, could improve the diagnosis and prognosis 
of PCa, and they could also become important therapeutic targets of the disease.
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De arachidonzuur metabole route: Een mogelijke 
toepassing voor diagnose en prognose van prostaatkanke
Samenvatting
Prostaatkanker (PCa) is bij de man de meest voorkomende vorm van kanker, in 
Europa werden in 2012 meer dan 400.000 gevallen gediagnosticeerd. Hoewel de 
introductie van de PSA test de behandeling verbeterde, leidt de lage specificiteit 
van de test tot overdiagnose en dus tot onnodige behandelingen van mannen 
die een laag risico hebben op progressie van de ziekte. Daarom zijn nieuwe en 
betrouwbare moleculaire markers nodig om de diagnose van PCa te verbeteren 
en om indolente patiënten te onderscheiden van hen die metastase krijgen.
In dit proefschrift proberen wij nieuwe marker metabolieten en marker eiwitten 
te identificeren in weefsel of lichaamsvloeistoffen, die de diagnose en/of 
prognose van PCa kunnen verbeteren. Daartoe hebben wij analytische methoden 
ontwikkeld om de rol van sommige metabolieten en eiwitten te onderzoeken, in 
het bijzonder de moleculen verbonden aan de arachidonzuur metabole route.
Wij hebben gerichte metabolomics benaderingen in serum toegepast om na te 
gaan of de concentraties van moleculen in twee verschillende metabole routes 
gebruikt kunnen worden voor de diagnose en prognose van PCa. Voor tryptofaan 
en voor een van zijn metabolieten (kynurenine) hebben we een HPLC methode 
toegepast met fluorescentie detectie. Serum monsters zijn gebruikt van enerzijds 
oudere mannen met lage PSA waarden en geen PCa en anderzijds van mannen 
met PCa. Er werden geen statistische verschillen gevonden tussen deze twee 
groepen en wij concluderen dan ook dat de concentraties van deze metabolieten 
(of hun verhouding) niet gebruikt kunnen worden als markers voor PCa.
Vervolgens hebben wij een UHPLC-MS/MS methode toegepast om de 
concentraties van arachidonzuur en enige van zijn metabolieten te meten in 
serum van PCa patiënten in verschillende stadia van de ziekte. Wij hebben een 
methode ontwikkeld om zes metabolieten van de arachidonzuur metabole route 
kwantitatief en gelijktijdig te meten en de resultaten hebben we gebruikt om 
de PCa diagnose te evalueren. In een kleine studie vonden wij dat een groep 
patiënten hogere concentraties van hydroxyeicosatetraenoic zuur (HETE) 
metabolieten hadden, vergeleken met de controle groep. Daarna hebben we 
dezelfde methode toegepast op een grotere en meer gedefinieerde groep 
patiënten, nu met verschillende stadia van PCa. We vonden dat een aantal 
patiënten met de meest agressieve vorm van PCa hoge concentraties hadden 
van deze HETE metabolieten en tegelijkertijd dat deze patiënten een lagere 
concentratie hadden van het arachidonzuur zelf. Deze, waarschijnlijk aan 
elkaar gerelateerde resultaten, kunnen gebruikt worden om recidief PCa na 
behandeling met radicaal prostatectomie te voorspellen.
In PCa en prostaat weefsel hebben wij kwantitatieve proteomics gebruikt om 
eiwitten te identificeren die geassocieerd zijn met diagnose en prognose. Tevens 
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hebben wij geëvalueerd of een verandering in concentratie van arachidonzuur 
in verband gebracht kan worden met een ontregeling van bepaalde eiwitten 
verbonden aan de arachidonzuur metabole route. Daartoe hebben wij van 67 PCa 
weefselmonsters RNA isolatie toegepast en in de eiwitfractie daarvan hebben 
wij, met proteomics technieken, eiwitten geïdentificeerd. Deze weefselmonsters 
bestonden uit 33 monsters van normaal aangrenzend weefsel en 34 PCa 
monsters. Van vier gevonden eiwitten hebben wij de expressie gevalideerd met 
immuunhistochemie en tevens hebben we microarrays van weefsel gebruikt 
om de prognostische waarde van de gevonden markers te evalueren. Een 
opmerkelijk bevinding was dat de productie van de eiwitten FASN, AGR2 en 
één eiwit van de arachidonzuur metabole route, namelijk TEBP, in patiënten 
met PCa significant  gestimuleerd is. De experimenten met de microarrays 
van weefsels toonden ook aan dat een laag percentage van positieve AGR2 
tumorcellen, als ook een laag percentage van LOX5 tumorcellen, voorspellers 
zijn voor recidief PCa na behandeling met radicaal prostatectomie.
In dit proefschrift hebben wij aangetoond dat bepaalde eiwitten en metabolieten 
in de arachidonzuur metabole route een belangrijke rol spelen in PCa. Om de 
karakterisatie van de structuren van de arachidonzuur metabolieten te verbeteren 
hebben wij de fragmentaties van arachidonzuur en verwante moleculen 
bestudeerd in aanwezigheid van de metaalionen Ca2+ en Mg2+. Toevoeging van 
deze metaalionen leidde tot structuurkarakteristieke fragmentaties waarbij met 
name de posities van de dubbele bindingen in de moleculen bepaald kunnen 
worden. Deze strategie kan verder geoptimaliseerd worden om vetzuren en 
lipiden beter met massaspectrometrie te identificeren om hun rol in bijvoorbeeld 
kanker beter in beeld te brengen.
Wij menen te hebben aangetoond dat de experimentele methodieken ontwikkeld 
in dit proefschrift kunnen bijdragen om de rol van het vetzuurmetabolisme en de 
rol van de arachidonzuur metabole route in PCa beter te kunnen begrijpen. Het 
kwantificeren van sleutelmetabolieten, zoals de hydroxyeicosatetraenoic zuren 
en arachidonzuur, als ook de enzymen geassocieerd met de metabole routes, 
kunnen de diagnose en prognose van PCa verbeteren en kunnen zij belangrijke 
therapeutische doelen worden in de bestrijding van PCa.
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